[487] Taksir TV, Johnson J, Maloney CL, Yandl E, Griffiths D, Thurberg BL, et al. Optimization of a histopathological biomarker for sphingomyelin accumulation in acid sphingomyelinase deficiency. J Histochem Cytochem 2012;60:620-9. https://doi.org/10.1369/0022155412451129.

[488] Wang NL, Chen L, Lu Y, Xie XB, Lin J, Abuduxikuer K, et al. The presence of vacuolated Kupffer cells raises a clinical suspicion of Niemann-Pick disease type C in neonatal cholestasis. Front Genet 2022;13. https://doi.org/10.3389/fgene.2022.867413.

[489] Rottach KG, Von Maydell RG, Das VE, Zivotofsky AZ, Discenna AO, Gordon JL, et al. Evidence for independent feedback control of horizontal and vertical saccades from Niemann-Pick type C disease. Vision Res 1997;37:3627-38. https://doi.org/10.1016/s0042-6989(96)00066-1.

[490] Galanaud D, Tourbah A, Lehericy S, Leveque N, Heron B, Billette V, et al. 24 month-treatment with miglustat of three patients with Niemann-Pick disease type C: follow up using brain spectroscopy. Mol.Genet.Metab 2009;96:55-8.

[491] Walterfang M, Fahey M, Desmond P, Wood A, Seal ML, Steward C, et al. White and gray matter alterations in adults with Niemann-Pick disease type C. Cross-sect Study 2010;75:49-56. https://doi.org/10.1212/WNL.0b1e3181e6210e.

[492] Totenhagen JW, Lope-Piedrafita S, Borbon IA, Yoshimaru ES, Erickson RP, Trouard TP. In vivo assessment of neurodegeneration in Niemann-Pick type C mice by quantitative T2 mapping and diffusion tensor imaging. J Magn Reson Imaging 2012;35:528-36.

[493] Masingue M, Adanyeguh I, Nadjar Y, Sedel F, Galanaud D, Mochel F. Evolution of structural neuroimaging biomarkers in a series of adult patients with Niemann-Pick type C under treatment. Orphanet J Rare Dis 2017;12:22. https://doi.org/10.1186/s13023-017-0579-3.

[494] Gburek-Augustat J, Groeschel S, Kern J, Beck-Woeld S, Just J, Harzer K, et al. Comparative analysis of cerebral magnetic resonance imaging changes in nontreated infantile, juvenile and adult patients with Niemann-Pick disease type C. Neuropediatrics 2020;51:037-44.

[495] Claudepierre T, Paques M, Simonutti M, Buard I, Sahel J, Maue RA, et al. Lack of Niemann Pick type C1 induces age-related degeneration in the mouse retina. Mol Cell Neurosci 2010;43:164-76.

[496] Hovakimyan M, Meyer A, Lukas J, Luo J, Gudziol V, Hummel T, et al. Olfactory deficits in Niemann-Pick type C1 (NPC1) disease. PloS One 2013;8. https://doi.org/10.1371/journal.pone.0082216.

[497] Palladino G, Loizzo S, Fortuna A, Canterini S, Palombi F, Erickson RP, et al. Visual evoked potentials of Niemann-Pick type C1 mice reveal an impairment of the visual pathway that is rescued by 2-hydroxypropyl-β-cyclodextrin. Orphanet J Rare Dis 2015;10:133. https://doi.org/10.1186/s13023-015-0348-0.

[498] Dannhausen K, Karlstetter M, Caramoy A, Volz C, Jägle H, Liebisch G, et al. Acid sphingomyelinase (aSMase) deficiency leads to abnormal microglia behavior and disturbed retinal function. Biochem Biophys Res Commun 2015;464:434-40. https://doi.org/10.1016/j.bbrc.2015.06.133.

[499] Wu BX, Fan J, Boyer NP, Jenkins RW, Koutalos Y, Hannun YA, et al. Lack of acid sphingomyelinase induces age-related retinal degeneration. PloS One 2015;10:e0133032. https://doi.org/10.1371/journal.pone.0133032.

[500] Havla J, Moser M, Sztatecsny C, Lotz-Havla AS, Maier EM, Hizli B, et al. Retinal axonal degeneration in Niemann-Pick type C disease. J Neurol 2020;267: 2070-82. https://doi.org/10.1007/s00415-020-09796-2.

[501] Hopf S, Hennermann JB, Schuster AK, Pfeiffer N, Pitz S. Vertical saccadic palsy and foveal retinal thinning in Niemann-Pick disease type C. PloS One 2021;16:e0252825. https://doi.org/10.1371/journal.pone.0252825.

[502] Rava A, La Rosa P, Palladino G, Dragotto J, Totaro A, Tiberi J, et al. The appearance of phagocytic microglia in the postnatal brain of Niemann Pick type C mice is developmentally regulated and underscores shortfalls in fine odor discrimination. J Cell Physiol 2022;237:4563-79. https://doi.org/10.1002/jcp.30909.

[503] Walterfang M, Di Biase MA, Cropley VL, Scott AM, O'Keefe G, Velakoulis D, et al. Imaging of neuroinflammation in adult Niemann-Pick type C disease: A cross-sectional study. Neurology 2020;94:e1716-25. https://doi.org/10.1212/wnl.000000000009287.

[504] El-Masri S, Malpas CB, Evans A, Walterfang M. Clinical correlates of movement disorders in adult Niemann-Pick type C patients measured via a Personal KinetiGraph. Neurol Sci 2022;43:6339-47. https://doi.org/10.1007/s10072-022-06308-0.

[505] Solomon BI, Munoz AM, Sinaii N, Farhat NM, Smith AC, Bianconi S, et al. Phenotypic expression of swallowing function in Niemann-Pick disease type C1. Orphanet J Rare Dis 2022;17. https://doi.org/10.1186/s13023-022-02472-w.

[506] Haider A, Zhao C, Wang L, Xiao Z, Rong J, Xia X, et al. Assessment of cholesterol homeostasis in the living human brain. Sci Transl Med 2022;14:eadc9967. https://doi.org/10.1126/scitranslmed.adc9967.

[507] Ancien F, Pucci F, Rooman M. In silico analysis of the molecular-level impact of SMPD1 variants on Niemann-Pick disease severity. Int J Mol Sci 2021;22. https://doi.org/10.3390/ijms22094516.

[508] Verot L, Chikh K, Freydiere E, Honore R, Vanier MT, Millat G. Niemann-Pick C disease: functional characterization of three NPC2 mutations and clinical and molecular update on patients with NPC2. Clin Genet 2007;71:320-30. https://doi.org/10.1111/j.1399-0004.2007.00782.x.

[509] Fancello T, Dardis A, Rosano C, Tarugi P, Tappino B, Zampieri S, et al. Molecular analysis of NPC1 and NPC2 gene in 34 Niemann-Pick C Italian Patients: identification and structural modeling of novel mutations. Neurogenetics 2009; 10:229-39. https://doi.org/10.1007/s10048-009-0175-3.

[510] Elghobashi-Meinhardt N. Niemann-Pick type C disease: A QM/MM study of conformational changes in cholesterol in the NPC1(NTD) and NPC2 binding pockets. Biochemistry 2014;53:6603-14. https://doi.org/10.1021/bi500548f.

[511] Vadlamudi Y, Muthu K, Kumar MS. Structural exploration of acid sphingomyelinase at different physiological pH through molecular dynamics and docking studies. RSC Adv 2016;6:74859-73. https://doi.org/10.1039/c6ra16584b.

[512] Wang C, Scott SM, Subramanian K, Loguercio S, Zhao P, Hutt DM, et al. Quantitating the epigenetic transformation contributing to cholesterol homeostasis using Gaussian process. Nat Commun 2019;10. https://doi.org/10.1038/s41467-019-12969-x.

[513] Wheeler S, Schmid R, Sillence DJ. Lipid-protein interactions in Niemann-Pick type C disease: insights from molecular modeling. Int J Mol Sci 2019;20. https://doi.org/10.3390/ijms20030717.

[514] Dubey V, Bozorg B, Wustner D, Khandela H. Cholesterol binding to the sterolsensing region of Niemann Pick C1 protein confines dynamics of its N-terminal domain. PLoS Comput Biol 2020;16. https://doi.org/10.1371/journal.pcbi.1007554.

[515] Elghobashi-Meinhardt N. Cholesterol transport in wild-type NPC1 and P691S: molecular dynamics simulations reveal changes in dynamical behavior. Int J Mol Sci 2020;21. https://doi.org/10.3390/ijms21082962.

[516] Yoon HJ, Jeong H, Lee HH, Jang S. Molecular dynamics study with mutation shows that N-terminal domain structural re-orientation in Niemann-Pick type C1 is required for proper alignment of cholesterol transport. J Neurochem 2021;156: 967-78. https://doi.org/10.1111/jnc.15150.

[517] Schachtner R, Lutter D, Knollmuller P, Tome AM, Theis FJ, Schmitz G, et al. Knowledge-based gene expression classification via matrix factorization. Bioinformatics 2008;24:1688-97. https://doi.org/10.1093/bioinformatics/btn245.

[518] Soufan O, Ba-alawi W, Magana-Mora A, Essack M, Bajic VB. DPubChem: a web tool for QSAR modeling and high-throughput virtual screening. Sci Rep 2018;8. https://doi.org/10.1038/s41598-018-27495-x.

[519] Parolo S, Masononi D, Bora P, Ramponi A, Kaddi C, Azer K, et al. Reconstruction of the cytokine signaling in lysosomal storage diseases by literature mining and network analysis. Front Cell Dev Biol 2021;9. https://doi.org/10.3389/fcell.2021.703489.

[520] Moreno-Barea FJ, Franco L, Elizondo D, Grootveld M. Application of data augmentation techniques towards metabolomics. Comput Biol Med 2022;148. https://doi.org/10.1016/j.combiomed.2022.105916.

[521] Bielschowsky M. Amautorische Idiotie und lipoidzellige Sploenohepatomegalie. J Psychol Neur 1928:33.

[522] Stein E. The causal meaning of the chemical changes for the pathology of the brain with Niemann-pickscher disease. Relationship between Niemann-Pickscher disease and infantile amaurotic Idiocy (typus tay-sachs). Virchows Arch Pathol Anatom Physiol Klinische Med 1932;284:867-79. https://doi.org/10.1007/bf01944065.

[523] Levade T, Gatt S. Uptake and intracellular degradation of fluorescent sphingomyelin by fibroblasts from normal individuals and a patient with Niemann-Pick disease. Biochim Biophys Acta 1987;918:250-9. https://doi.org/10.1016/0005-2760(87)90228-1.

[524] Levade T, Salvayre R, Maret A, Dousteblay L. Evidence for both endogenous and exogenous sources of the sphingomyelin storage in lymphoid-cell lines from patients with Niemann-Pick disease type-A and type-B. J Inherit Metab Dis 1988; 11:151-7. https://doi.org/10.1007/bf01799864.

[525] Karten B, Vance DE, Campenot RB, Vance JE. Cholesterol accumulates in cell bodies, but is decreased in distal axons, of Niemann-Pick C1-deficient neurons. J. Neurochem. 2002;83:1154-63.

[526] Reid PC, Sugii S, Chang TY. Trafficking defects in endogenously synthesized cholesterol in fibroblasts, macrophages, hepatocytes, and glial cells from Niemann-Pick type C1 mice. J Lipid Res 2003;44:1010-9.

[527] Elrick MJ, Yu T, Chung C, Lieberman AP. Impaired proteolysis underlies autophagic dysfunction in Niemann-Pick type C disease. Hum Mol Genet 2012;21: 4876-87. https://doi.org/10.1093/hmgdds324.

[528] Leventhal AR, Chen WG, Tall AR, Tabas I. Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. J Biol Chem 2001; 276:44976-83. https://doi.org/10.1074/jbc.M106455200.

[529] Sarna J, Miranda SRP, Schuchman EH, Hawkes R. Patterned cerebellar Purkinje cell death in a transgenic mouse model of Niemann Pick type A/B disease. Eur J Neurosci 2001;13:1873-80. https://doi.org/10.1046/j.953-816x.2001.01564.x.

[530] Shihabuddin LS, Numan S, Huff MR, Dodge JC, Clarke J, Macauley SL, et al. Intracerebral transplantation of adult mouse neural progenitor cells into the Niemann-Pick-A mouse leads to a marked decrease in lysosomal storage pathology. J Neurosci 2004;24:10642-51. https://doi.org/10.1523/jneurosci.3584-04.2004.

[531] Scandroglio F, Venkata JK, Loberto N, Prioni S, Schuchman EH, Chigorno V, et al. Lipid content of brain, brain membrane lipid domains, and neurons from acid sphingomyelinase deficient mice. J Neurochem 2008;107:329-38. https://doi.org/10.1111/j.1471-4159.2008.05591.x.

[532] Butler JD, Vanier MT, Pentchev PG. Niemann-Pick C disease: cystine and lipids accumulate in the murine model of this lysosomal cholesterol lipidosis. Biochem Biophys Res Commun 1993;196:154-9. https://doi.org/10.1006/bbrc.1992228.

[533] Hulkova H, Ledvinova J, Asfaw B, Koubek K, Kopriva K, Elleder M. Lactosylceramide in lysosomal storage disorders. A comparative immunohistochemical and biochemical study. Virchows Arch 2005;447:31-44. https://doi.org/10.1007/s00428-005-1246-y.

[534] Goldin E, Roff CF, Miller SPF, Rodriguezlafrasse C, Vanier MT, Brady RO, et al. Type-C Niemann-Pick disease - a murine model of the lysosomal cholesterol
lipidosis accumulates sphingosine and sphinganine in liver. *Biochim Biophys Acta* 1992;1127:303-11. https://doi.org/10.1016/0005-2760(92)90236-0.

[535] Rodriguez-Lafrasse C, Rousson R, Pentchev PG, Louisot P, Vanier MT. Free sphingoid bases in tissues from patients with type-C Niemann-Pick disease and other lysosomal storage disorders. *BBA-Mol Basis Res* 1994;1226:138-44. https://doi.org/10.1016/0925-4439(94)90021-3.

[536] te Vruchte D, Lloyd-Evans E, Veldman RJ, Neville DC, Dwek RA, Platt FM, et al. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport. *J.Biol.Chem.* 2004;279:26167-75.

[537] Lloyd-Evans E, Morgan AJ, He X, Smith DA, Elliot-Smith E, Silence DJ, et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. *Nat.Med.* 2008;14:1247-55.

[538] Gläser A, Hammerl F, Gräler MH, Coldewey SM, Völkner C, Frech MJ, et al. Identification of brain-specific treatment effects in NPC1 disease by focusing on cellular and molecular changes of sphingosine-1-phosphate metabolism. *Int J Mol Sci* 2020:21. https://doi.org/10.3390/ijms21124502.

[539] Rouser G, Kritchevsky G, Yamamoto A, Knudson AG, Simon G. Accumulation of a glycerolphospholipid in classical Niemann-Pick disease. *Lipids* 1968;3. https://doi.org/10.1007/bf02531203. 287+.

[540] Gruenberg J. Life in the lumen: The multivesicular endosome. *Traffic* 2020;21: 76-93. https://doi.org/10.1111/tra.12715.

[541] Taniguchi M, Shinoda Y, Ninomiya H, Vanier MT, Ohno K. Sites and temporal changes of gangliosides GM1/GM2 storage in the Niemann-Pick disease type C mouse brain. *Brain Dev* 2001;23:414-21.

[542] Sugimoto Y, Ninomiya H, Ohsaki Y, Higaki K, Davies JP, Ioannou YA, et al. Accumulation of cholera toxin and GM1 ganglioside in the early endosome of Niemann-Pick C1-deficient cells. *Proc Natl Acad Sci USA* 2001;98:12391-6.

[543] Zervas M, Dobrenis K, Walkley SU. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. *J.Neuropathol.Exp.Neurol.* 2001;60:49-64.

[544] Abdul-Hammed M, Breiden B, Adebayo MA, Babalola JO, Schwarzmann G, Sandhoff K. Role of endosomal membrane lipids and NPC2 in cholesterol transfer and membrane fusion. *J.Biol.Res* 2010;51:1747-60. https://doi.org/10.1194/jlr. M003822.

[545] Devlin C, Pipalia NH, Liao X, Schuchman EH, Maxfield FR, Tabas I. Improvement in lipid and protein trafficking in Niemann-Pick C1 cells by correction of a secondary enzyme defect. *Traffic* 2010;11:601-15.

[546] Marques AR, Aten J, Ottenhoff R, van Roomen CP, Herrera Moro D, Claessen N, et al. Reducing GBA2 activity ameliorates neuropathology in Niemann-Pick type C mice. *PloS One* 2015;10:e0135889. https://doi.org/10.1371/journal.pone.0135889.

[547] Anheuser S, Breiden B, Sandhoff K. Membrane lipids and their degradation compounds control GM2 catabolism at intralysosomal luminal vesicles. *J.Biol Res* 2019;60:1099-111. https://doi.org/10.1194/jlr.M092551.

[548] Hashimoto N, Matsumoto I, Takahashi H, Ashikawa H, Nakamura H, Murayama T. Cholesterol-dependent increases in glucosylceramide synthase activity in Niemann-Pick disease type C model cells: Abnormal trafficking of endogenously formed ceramide metabolites by inhibition of the enzyme. *Neuropharmacology* 2016;110:458-69. https://doi.org/10.1016/j.neuropharm.2016.08.011.

[549] Breiden B, Sandhoff K. Mechanism of secondary ganglioside and lipid accumulation in lysosomal disease. *Int J Mol Sci* 2020:21. https://doi.org/ 10.3390/ijms21072566.

[550] Pluvination JV, Sun J, Claes C, Flynn RA, Haney MS, Iram T, et al. The CD22-IGF2R interaction is a therapeutic target for microglial lysosome dysfunction in Niemann-Pick type C. *Sci Transl Med* 2021;13. https://doi.org/10.1126/ scitranslmed.abg2919. eabg2919.

[551] Cheung NS, Koh CH, Bay BH, Qi RZ, Choy MS, Li QT, et al. Chronic exposure to U1866A induces apoptosis in cultured murine cortical neurons. *Biochem. Biophys.Res.Commun.* 2004;315:408-17.

[552] Wang MD, Franklin V, Sundaram M, Kiss RS, Ho K, Gallant M, et al. Differential regulation of ATP binding cassette protein A1 expression and ApoA-I lipidation by Niemann-Pick type C1 in murine hepatocytes and macrophages. *J.Biol.Chem.* 2007;282:22525-33.

[553] Higashi Y, Murayama S, Pentchev PG, Suzuki K. Cerebellar degeneration in the Niemann-Pick type C mouse. *Acta Neuropathol (Berl.)* 1993;85:175-84.

[554] Sarna JR, Larouche M, Marzban H, Sillitoe RV, Rancourt DE, Hawkes R. Patterned Purkinje cell degeneration in mouse models of Niemann-Pick type C disease. *J.Comp.Neurol.* 2003;456:279-91.

[555] Fiorenza MT, La Rosa P, Canterini S, Erickson RP. The cerebellum in Niemann- Pick C disease: mouse versus man. *Cerebellum* 2022. https://doi.org/10.1007/ s12311-021-01347-3.

[556] Nonneman A, Criem N, Lewandowski SA, Nuyts R, Thal DR, Pfrieger FW, et al. Astrocyte-derived Jagged-1 mitigates deleterious Notch signaling in amyotrophic lateral sclerosis. *Neurobiol Dis* 2018;119:26-40. https://doi.org/10.1016/j. nbd.2018.07.012.

[557] Maatouk L, Yi C, Carrillo-de Sauvage MA, Compagnon AC, Hunot S, Ezan P, et al. Glucocorticoid receptor in astrocytes regulates midbrain dopamine neurodegeneration through connexin hemichannel activity. *Cell Death Differ* 2019;26:580-96. https://doi.org/10.1038/s41418-018-0150-3.

[558] Brandebura AN, Paumier A, Onur TS, Allen NJ. Astrocyte contribution to dysfunction, risk and progression in neurodegenerative disorders. *Nat Rev Neurosci* 2022. https://doi.org/10.1038/s41583-022-00641-1.

[559] Elrick MJ, Pacheco CD, Yu T, Dadgar N, Shakkottai VG, Ware C, et al. Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. *Hum.Mol.Genet.* 2010;19:837-47.

[560] Chung C, Puthanveetil P, Ory DS, Lieberman AP. Genetic and pharmacological evidence implicates cathepsins in Niemann-Pick C cerebellar degeneration. *Hum Mol Genet* 2016;25:1434-46. https://doi.org/10.1093/hmg/dw025.

[561] Karten B, Hayashi H, Francis GA, Campenot RB, Vance DE, Vance JE. Generation and function of astrogliar lipoproteins from Niemann-Pick type C1-deficient mice. *Biochem.J.* 2005;387:779-88.

[562] Diezel PB. Histochemical studies on primary lipoidoses: amaurotic idioogy, gargoylism, Niemann-Pick's disease, Gaucher's diseases with special reference to the central nervous system. *Virchows Archiv Pathol Anatom Physiol Klinische Med* 1954;326:89-118. https://doi.org/10.1007/bf02438653.

[563] Gabande-Rodriguez E, Perez-Canamas A, Soto-Huelin B, Mitroi DN, Sanchez- Redondo S, Martinez-Saez E, et al. Lipid-induced lysosomal damage after demyelination corrupts microglia protective function in lysosomal storage disorders. *EMBO J* 2019;38. https://doi.org/10.15252/embj.201899553.

[564] Seo Y, Kim HS, Kang I, Choi SW, Shin TH, Shin JH, et al. Cathepsin S contributes to microglia-mediated olfactory dysfunction through the regulation of Cx3cl1- Cx3cr1 axis in a Niemann-Pick disease type C1 model. *Glia* 2016;64:2291-305. https://doi.org/10.1002/glia.23077.

[565] Kavetsky L, Green KK, Boyle BR, Yousufzai FAK, Padron ZM, Melli SE, et al. Increased interactions and engulfment of dendrites of microglia precede Purkinje cell degeneration in a mouse model of Niemann Pick Type-C. *Sci Rep* 2019;9: 14722. https://doi.org/10.1038/s41598-019-51246-1.

[566] Barthelemy A, Demais V, Stancu I-C, Vasile E, Houben T, Reber M, et al. Glial contribution to cyclodextrin-mediated reversal of cholesterol accumulation in murine NPC1-deficient neurons *in vivo*. *bioRxiv* 2021. https://doi.org/10.1101/ 2021.04.08.438990. 2021.04.08.438990.

[567] Colombo A, Dinkel L, Muller SA, Sebastian Monaros L, Schifferer M, Cantutti- Castelvetri L, et al. Loss of NPC1 enhances phagocytic uptake and impairs lipid trafficking in microglia. *Nat Commun* 2021;12:1158. https://doi.org/10.1038/ s41467-021-21428-5.

[568] Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system vesicular vessels. *Nature* 2015; 523. https://doi.org/10.1038/nature14432. 337+.

[569] Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, et al. Aural lymphatic vascular system that drains brain interstitial fluid and macromolecules. *J Exp Med* 2015;212:991-9. https://doi.org/10.1084/jem.20142290.

[570] Møllård K, Beilinck FRM, Kusk P, Miyakoshi LM, Delle C, Plá V, et al. A mesothelium divides the subarachnoid space into functional compartments. *Science* 2023;379:84-8. https://doi.org/10.1126/science.adc8810.

[571] Rustenhoven J, Kipnis J. Brain borders at the central stage of neuroimmunology. *Nature* 2022;612:417-29. https://doi.org/10.1038/s41586-022-05474-7.

[572] Csepegci C, Jiang M, Frolov A. Somatic cell plasticity and Niemann-Pick type C2 protein: adipocyte differentiation and function. *J.Biol.Chem* 2010;285:30347-54. https://doi.org/10.1074/jbc.M110.135939.

[573] Roszell BR, Tao J-Q, Yu KJ, Gao L, Huang S, Ning Y, et al. Pulmonary abnormalities in animal models due to Niemann-Pick Type C1 (NPC1) or C2 (NPC2) disease. *PloS One* 2013;8:e67084. https://doi.org/10.1371/journal.pone.0067084.

[574] Rodriguez-Gil JL, Watkins-Chow DE, Baxter LL, Yokoyama T, Zerfas PM, Starost MF, et al. NPC1 deficiency in mice is associated with fetal growth restriction, neonatal lethality and abnormal lung pathology. *J Clin Med* 2020:9. https://doi.org/10.3390/jcm9010012.

[575] Suresh S, Yan Z, Patel RC, Patel YC, Patel SC. Cellular cholesterol storage in the Niemann-Pick disease type C mouse is associated with increased expression and defective processing of apolipoprotein E. *J.Neurochem.* 1998;70:242-51.

[576] German DC, Liang CL, Song T, Yazdani U, Xie C, Dietschy JM. Neurodegeneration in the Niemann-Pick type C mouse: glial involvement. *Neuroscience* 2002;109:437-50.

[577] Suzuki H, Sakiyama T, Harada N, Abe M, Tadokoro M. Pathologic changes of glial cells in murine model of Niemann-Pick disease type C: immunohistochemical, lectin-histochemical and ultrastructural observations. *Pediatr.Int.* 2003;45:1-4.

[578] Baudry M, Yao Y, Simmons D, Liu J, Bi X. Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: immunohistochemical observations of microglia and astroglia. *Exp Neurol* 2003;184:887-903. https:// doi.org/10.1016/s0014-4886(03)00345-5.

[579] Chen G, Li HM, Chen YR, Gu XS, Duan S. Decreased estradiol release from astrocytes contributes to the neurodegeneration in a mouse model of Niemann- Pick disease type C. *GLIA* 2007;55:1509-18.

[580] Peake KB, Campenot RB, Vance DE, Vance JE. Niemann-Pick Type C1 deficiency in microglia does not cause neuron death in vitro. *Biochim.Biophys.Acta* 2011; 1812:1121-9.

[581] Yan X, Yang F, Lukas J, Witt M, Wree A, Rolfs A, et al. Hyperactive glial cells contribute to axonal pathologies in the spinal cord of Npc1 mutant mice. *Glia* 2014;62:1024-40. https://doi.org/10.1002/glia.22659.

[582] Seo Y, Kim H-S, Shin Y, Kang I, Choi SW, Yu K-R, et al. Excessive microglial activation aggravates olfactory dysfunction by impeding the survival of newborn neurons in the olfactory bulb of Niemann-Pick disease type C1 mice. *BBA-Mol Basis Res* 2014;1842:2193-203. https://doi.org/10.1016/j.bbadis.2014.08.005.

[583] Caporali P, Bruno F, Palladino G, Dragotto J, Petrosini L, Mangia F, et al. Developmental delay in motor skill acquisition in Niemann-Pick C1 mice reveals abnormal cerebellar morphogenesis. *Acta Neuropathologica. Communications* 2016:4. https://doi.org/10.1186/s40478-016-0370-z.

[584] Boyle BR, Melli SE, Altreche RS, Padron ZM, Yousufzai FAK, Kim S, et al. NPC1 deficiency impairs cerebellar postnatal development of microglia and climbing fiber refinement in a mouse model of Niemann-Pick disease type C. *Development* 2020:147. https://doi.org/10.1242/dev.189019.
[585] Berger A, Rosenthal D, Spiegel S. Sphingosylphosphocholine, a signaling molecule which accumulates in Niemann-Pick disease type-A, stimulates dna-binding activity of the transcription activator protein AP-1. Proc Natl Acad Sci U S A 1995; 92:5885-9. https://doi.org/10.1073/pnas.92.13.5885.

[586] Tam C, Idone V, Devlin C, Fernandes MC, Flannery A, He XX, et al. Exocytosis of acid sphingomyelinase by wounded cells promotes endocytosis and plasma membrane repair. J Cell Biol 2010;189:1027-38. https://doi.org/10.1083/jcb.201003053.

[587] Koike T, Ishida G, Taniguchi M, Higaki K, Ayaki Y, Saito M, et al. Decreased membrane fluidity and unsaturated fatty acids in Niemann-Pick disease type C fibroblasts. BBA-Mol Basis Dis 1998;1406:327-35. https://doi.org/10.1016/s0925-4439(98)00019-2.

[588] Ko DC, Gordon MD, Jin JY, Scott MP. Dynamic movements of organelles containing Niemann-Pick C1 protein: NPC1 involvement in late endocytic events. Mol.Biol.Cell 2001;12:601-14.

[589] Zhang M, Dwyer NK, Love DC, Cooney A, Comly M, Neufeld E, et al. Cessation of rapid late endosomal tubulovesicular trafficking in Niemann-Pick type C1 disease. Proc Natl Acad Sci U S A 2001;98:4466-71. https://doi.org/10.1073/pnas.081070898.

[590] Lebrand C, Corti M, Goodson H, Cosson P, Cavalli V, Mayran N, et al. Late endosome motility depends on lipids via the small GTPase Rab7. EMBO J 2002; 21:1289-300. https://doi.org/10.1093/emboj/21.6.1289.

[591] Rocha N, Kuijl C, van der Kant R, Janssen L, Houben D, Janssen H, et al. Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 (Glued) and late endosome positioning. J Cell Biol 2009;185:1209-25. https://doi.org/10.1083/jcb.200811005.

[592] Sterling FR, D'Amico J, Drumfield AM, Huegel KL, Vaughan PS, Morris K, et al. STARD9 is a novel lysosomal kinesin required for membrane tubulation, cholesterol transport and Purkinje cell survival. J Cell Sci 2023:136. https://doi.org/10.1242/jcs.260662.

[593] Frolov A, Zielinski SE, Crowley JR, Dudley-Rucker N, Schaffer JE, Ory DS. NPC1 and NPC2 regulate cellular cholesterol homeostasis through generation of low density lipoprotein cholesterol-derived oxysterols. J Biol Chem 2003;278: 25517-25. https://doi.org/10.1074/jbc.M302588200.

[594] Ganley IG, Pfeffer SR. Cholesterol accumulation sequesters Rab9 and disrupts late endosome function in NPC1-deficient cells. J Biol Chem 2006;281:17890-9. https://doi.org/10.1074/jbc.M601679200.

[595] Reddy JV, Ganley IG, Pfeffer SR. Clues to neuro-degeneration in Niemann-Pick Type C disease from global gene expression profiling. PLoS.ONE. 2006;1:e19.

[596] Pacheco CD, Kunkel R, Lieberman AP. Autophagy in Niemann-Pick C disease is dependent upon Beclin-1 and responsive to lipid trafficking defects. Hum.Mol. Genet. 2007;16:1495-503.

[597] Shen D, Wang X, Li X, Zhang X, Yao Z, Dibble S, et al. Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release. Nat.Commun. 2012;3:731.

[598] Strauss K, Goebel C, Runz H, Mobius W, Weiss S, Feussner I, et al. Exosome secretion ameliorates lysosomal storage of cholesterol in Niemann-Pick Type C disease. J Biol Chem 2010;285:26279-88. https://doi.org/10.1074/jbc.M110.134775.

[599] Davis OB, Shin HR, Lim C-Y, Wu EY, Kukurugya M, Maher CF, et al. NPC1-mTORC1 signaling couples cholesterol sensing to organelle homeostasis and is a targetable pathway in Niemann-Pick type C. Dev Cell 2021;56:260-276.e7. https://doi.org/10.1016/j.devcel.2020.11.016.

[600] Kosicek M, Gudelj I, Horvatic A, Jovic T, Vuckovic F, Lauc G, et al. N-glycme of the lysosomal glycolyx is altered in Niemann-Pick type C disease (NPC) model cells. Mol Cell Proteomics 2018;17:631-42. https://doi.org/10.1074/mcp.RA117.000129.

[601] Lusa S, Blom TS, Eskelinen EL, Kuismanen JE, Simons C, et al. Depletion of rafts in late endocytic membranes is controlled by NPC1-dependent recycling of cholesterol to the plasma membrane. J Cell Sci 2001;114:1893-900.

[602] Choi HY, Karten B, Chan T, Vance JE, Greer WL, Heidenreich RA, et al. Impaired ABCA1-dependent lipid efflux and hypoaliphalipoproteinemia in human Niemann-Pick type C disease. J.Biol.Chem. 2003;278:32569-77.

[603] Kirkegaard T, Roth AG, Petersen NHT, Mahalka AK, Olsen OD, Moilanen I, et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 2010;463:549-U171. https://doi.org/10.1038/nature08710.

[604] Yambire KF, Fernandez-Mosquera L, Steinfeld R, Muhle C, Ikonen E, Milosevic I, et al. Mitochondrial biogenesis is transcriptionally repressed in lysosomal lipid storage diseases. Elife 2019:8. https://doi.org/10.7554/eLife.39598.

[605] Van Hoecke L, Van Cauwenberge C, Dominko K, Van Imschoot G, Van Wonterghem E, Castelein J, et al. Involvement of the choroid plexus in the pathogenesis of Niemann-Pick disease type C. Front Cell Neurosci 2021:15. https://doi.org/10.3389/fncel.2021.757482.

[606] Li X, Xu M, Pitzer AL, Xia M, Boini KM, Li PL, et al. Control of autophagy maturation by acid sphingomyelinase in mouse coronary arterial smooth muscle cells: protective role in atherosclerosis. J Mol Med 2014;92:473-85. https://doi.org/10.1007/s00109-014-1120-y.

[607] Butler A, He XX, Gordon RE, Wu HS, Gatt S, Schuchman EH. Reproductive pathology and sperm physiology in acid sphingomyelinase-deficient mice. Am J Math 2002;161:1061-75. https://doi.org/10.1016/s0022-9440(10)64267-8.

[608] Fan J, Akabane H, Graham SN, Richardson LL, Zhu GZ. Sperm defects in mice lacking a functional Niemann-Pick C1 protein. Mol Reprod Dev 2006;73:1284-91. https://doi.org/10.1002/mrd.20559.

[609] Busso D, Onate-Alvarado MJ, Balboa E, Zlanzou S, Moreno RD. Female infertility due to anovulation and defective steroidogenesis in NPC2 deficient

mice. Mol Cell Endocrinol 2010;315:299-307. https://doi.org/10.1016/j.mce.2009.10.011.

[610] Busso D, Onate-Alvarado MJ, Balboa E, Castro J, Lizama C, Morales G, et al. Spermatozoa from mice deficient in Niemann-Pick disease type C2 (NPC2) protein have defective cholesterol content and reduced in vitro fertilising ability. Reprod Fertil Dev 2014;26:609-21. https://doi.org/10.1071/rd12059.

[611] Moles A, Tarrats N, Fernandez-Checa JC, Mari M. Cathepsin B overexpression due to acid sphingomyelinase ablation promotes liver fibrosis in Niemann-Pick disease. J Biol Chem 2012;287:1178-88. https://doi.org/10.1074/jbc.M111.272393.

[612] Schedin S, Sindelar PJ, Pentchev P, Brunk U, Dallner G. Peroxisomal impairment in Niemann-Pick type C disease. J Biol Chem 1997;272:6245-51. https://doi.org/10.1074/jbc.272.10.6245.

[613] Christianou H, Vanier MT, Santambrogio P, Arosio P, Kleijer WJ, Harzer K. Deficient ferritin immunoreactivity in tissues from Niemann-Pick type C patients: extension of findings to fetal tissues, H and L ferritin isoforms, but also one case of the rare Niemann-Pick C2 complementation group. Mol Genet Metab 2000;70: 196-202. https://doi.org/10.1006/mgme.2000.3004.

[614] Hung YH, Faux NG, Killilea DW, Yanjanin N, Firnkes S, Volitakis I, et al. Altered transition metal homeostasis in Niemann-Pick disease, type C1. Metalomics 2014;6:542-53. https://doi.org/10.1039/c3mt00308f.

[615] Vainio S, Bykov I, Hermansson M, Jokitalo E, Somerharju P, Ikonen E. Defective insulin receptor activation and altered lipid rafts in Niemann-Pick type C disease hepatocytes. Biochem J 2005;391:465-72. https://doi.org/10.1042/bj20050460.

[616] Marí M, Caballero F, Colell A, Morales A, Caballeria J, Fernandez A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006;4:185-98. https://doi.org/10.1016/j.cmet.2006.07.006.

[617] Torres S, Matías N, Baulies A, Núñez S, Alarcon-Vila C, Martínez L, et al. Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease. Redox Biol 2017;11:60-72. https://doi.org/10.1016/j.redox.2016.11.010.

[618] Balboa E, Marin T, Oyarzun JE, Contreras PS, Hardt R, Van den Bosch T, et al. Proteomic analysis of Niemann-Pick type C hepatocytes reveals potential therapeutic targets for liver damage. Cells 2021:10. https://doi.org/10.3390/cells10082159.

[619] Torres S, Solsona-Vilarrasa E, Nunez S, Matias N, Insausti-Urkia N, Castro F, et al. Acid ceramidase improves mitochondrial function and oxidative stress in Niemann-Pick type C disease by repressing STARD1 expression and mitochondrial cholesterol accumulation. Redox Biol 2021:45. https://doi.org/10.1016/j.redox.2021.102052.

[620] Utermohlen O, Karow U, Lohler J, Kronke M. Severe impairment in early host defense against Listeria monocytogenes in mice deficient in acid sphingomyelinase. J Immunol 2003;170:2621-8. https://doi.org/10.4049/jimmunol.170.5.2621.

[621] Schramm M, Herz J, Haas A, Kronke M, Utermohlen O. Acid sphingomyelinase is required for efficient phago-lysosomal fusion. Cell Microb 2008;10:1839-53. https://doi.org/10.1111/j.1462-5822.2008.01169.x.

[622] Zhang JR, Coleman T, Langmade SJ, Scherrer DE, Lane R, Lanier MH, et al. Niemann-Pick C1 protects against atherosclerosis in mice via regulation of macrophage intracellular cholesterol trafficking. J Clin Invest 2008;118:2281-90. https://doi.org/10.1172/jci32561.

[623] Schwerd T, Pandey S, Yang HT, Bagola K, Jameson E, Jung J, et al. Impaired antibacterial autophagy links granulomatous intestinal inflammation in Niemann-Pick disease type C1 and XIAP deficiency with NOD2 variants in Crohn's disease. Gut 2017;66:1060-73. https://doi.org/10.1136/gutj2015-310382.

[624] Canonico B, Cesarini E, Salucci S, Luchetti F, Falcieri E, Di Sario G, et al. Defective autophagy, mitochondrial clearance and lipophagy in Niemann-Pick type B lymphocytes. PLoS One 2016:11. https://doi.org/10.1371/journal.pone.0165780.

[625] Nix M, Stoffel W. Perturbation of membrane microdomains reduces mitogenic signaling and increases susceptibility to apoptosis after T cell receptor stimulation. Cell Death Differ 2000;7:413-24. https://doi.org/10.1038/sj.cdd.4400666.

[626] Herz J, Pardo J, Kashkar H, Schramm M, Kuzmenkina E, Bos E, et al. Acid sphingomyelinase is a key regulator of cytotoxic granule secretion by primary T lymphocytes. Nat Immunol 2009;10:761-U121. https://doi.org/10.1038/ni.1757.

[627] Castiblanco D, Rudd-Schmidt JA, Noori T, Sutton VR, Hung YH, Flinsenberg TWH, et al. Severely impaired CTL killing is a feature of the neurological disorder Niemann-Pick disease type C1. Blood 2022;139:1833-49. https://doi.org/10.1182/blood.2020131477.

[628] Melum E, Jiang XJ, Baker KD, Macedo MF, Fritsch J, Dowds CM, et al. Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin. Nat Immunol 2019;20. https://doi.org/10.1038/s41590-019-0504-0. 1644+.

[629] Sagiv Y, Hudspeth K, Mattner J, Schrantz N, Stern RK, Zhou D, et al. Cutting edge: impaired glycosphingolipid trafficking and NKT cell development in mice lacking Niemann-Pick type C1 protein. J Immunol 2006;177:26-30. https://doi.org/10.4049/jimmunol.177.1.26.

[630] Schumaj J, Facciotti F, Panza L, Michieletti M, Compostella F, Collmann A, et al. Differential alteration of lipid antigen presentation to NKT cells due to imbalances in lipid metabolism. Eur J Immunol 2007;37:1431-41. https://doi.org/10.1002/eji.200737160.

[631] Speak AO, Vruchte DT, Davis LC, Morgan AJ, Smith DA, Yanjanin NM, et al. Altered distribution and function of natural killer cells in murine and human Niemann-Pick disease type C1. Blood 2014;123:51-60. https://doi.org/10.1182/blood-2013-03-488692.
[632] Liao G, Yao Y, Liu J, Yu Z, Cheung S, Xie A, et al. Cholesterol accumulation is associated with lysosomal dysfunction and autophagic stress in Npc1 -/- mouse brain. Am.J.Pathol. 2007;171:962-75.

[633] Conte C, Arcuri C, Cataldi S, Mecca C, Codini M, Ceccarini MR, et al. Niemann-Pick type A disease: behavior of neutral sphingomyelinase and vitamin D receptor. Int J Mol Sci 2019;20. https://doi.org/10.3390/ijms20092365.

[634] Horoupanid DS, Yang SS. Paired helical filaments in neurovisceral lipidosis (Juvenile dystonic lipidosis). Ann Neurol 1978;4:404-11. https://doi.org/10.1002/ana.410040504.

[635] Love S, Bridges LR, Case CP. Neurofibrillary tangles in Niemann-Pick disease type C. Brain 1995;118(Pt 1):119-29.

[636] Auer IA, Schmid ML, Lee VM, Curry B, Suzuki K, Shin RW, et al. Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease. Acta Neuropathol 1995;90:547-51.

[637] Suzuki K, Parker CC, Pentchev PG, Katz D, Ghetti B, D'Agostino AN, et al. Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol (Berl) 1995;89:227-38.

[638] Henderson LP, Lin L, Prasad A, Paul CA, Chang TY, Maue RA. Embryonic striatal neurons from niemann-pick type C mice exhibit defects in cholesterol metabolism and neurotrophin responsiveness. J.Biol.Chem. 2000;275:20179-87.

[639] Sawamura N, Gong JS, Garver WS, Heidenreich RA, Ninomiya H, Ohno K, et al. Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J.Biol. Chem. 2001;276:10314-9.

[640] Bu B, Li J, Davies P, Vincent I. Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J.Neurosci. 2002;22:6515-25.

[641] Tuck BJ, Miller LVC, Katsinelos T, Smith AE, Wilson EL, Keeling S, et al. Cholesterol determines the cytosolic entry and seeded aggregation of tau. Cell Rep 2022;39:110776. https://doi.org/10.1016/j.celrep.2022.110776.

[642] Yamazaki T, Chang TY, Haass C, Ihara Y. Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-pick type C cells. J.Biol. Chem. 2001;276:4454-60.

[643] Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, et al. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J.Neurosci. 2002;22:1679-89.

[644] Burns M, Gaynor K, Olm V, Mercken M, LaFrancois J, Wang L, et al. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J.Neurosci. 2003;23:5645-9. https://doi.org/10.1523/JNEUROSCI.23-13-05645.2003.

[645] Jin LW, Shie FS, Maezawa I, Vincent I, Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am.J. Pathol. 2004;164:975-85.

[646] Kodam A, Maulik M, Peake K, Amritraj A, Vetrivel KS, Thinakaran G, et al. Altered levels and distribution of amyloid precursor protein and its processing enzymes in Niemann-Pick type C1-deficient mouse brain. Glia 2010;58:1267-81. https://doi.org/10.1002/glia.21001.

[647] Mattsson N, Olsson M, Gustavsson MK, Kosicek M, Malnar M, Mansson JE, et al. Amyloid-beta metabolism in Niemann-Pick C disease models and patients. Metab Brain Dis 2012;27:573-85.

[648] Tashiro Y, Yamazaki T, Shimada Y, Ohno-Iwashita Y, Okamoto K. Axon-dominant localization of cell-surface cholesterol in cultured hippocampal neurons and its disappearance in Niemann-Pick type C model cells. Eur.J.Neurosci. 2004;20:2015-21.

[649] Wu YP, Mizukami H, Matsuda J, Saito Y, Proia RL, Suzuki K. Apoptosis accompanied by up-regulation of TNF-alpha death pathway genes in the brain of Niemann-Pick type C disease. Mol Genet Metab 2005;84:9-17. https://doi.org/10.1016/j.ymgme.2004.08.017.

[650] Bi XN, Liu JH, Yao YQ, Baudry M. Lynch G. Deregulation of the phosphatidylinositol-3 kinase signaling cascade is associated with neurodegeneration in Npc1 -/- mouse brain. Am J Pathol 2005;167:1081-92. https://doi.org/10.1016/s0002-9440(10)61197-2.

[651] Yang SR, Kim SJ, Byun KH, Hutchinson B, Lee BH, Michikawa M, et al. NPC1 gene deficiency leads to lack of neural stem cell self-cells activation and abnormal differentiation through activation of p38 mitogen-activated protein kinase signaling. Stem Cells 2006;24:292-8. https://doi.org/10.1634/stemcells.2005-0221.

[652] Nusca S, Canterini S, Palladino G, Bruno F, Mangia F, Erickson RP, et al. A marked paucity of granule cells in the developing cerebellum of the Npc1(-/-) mouse is corrected by a single injection of hydroxypropyl-beta-cyclodextrin. Neurobiol Dis 2014;70:117-26. https://doi.org/10.1016/j.nbd.2014.06.012.

[653] Amritraj A, Peake K, Kodam A, Salio C, Merighi A, Vance JE, et al. Increased activity and altered subcellular distribution of lysosomal enzymes determine neuronal vulnerability in Niemann-Pick type C1-deficient mice. Am.J.Pathol. 2009;175:2540-56.

[654] Lee H, Lee JK, Park MH, Hong YR, Marti HH, Kim H, et al. Pathological roles of the VEGF/Sphk pathway in Niemann-Pick type C neurons. Nat Commun 2014;5:5514. https://doi.org/10.1038/ncomms6514.

[655] Canterini S, Dragotij J, Dardis A, Zampieri S, de Stefano ME, Mangia F, et al. Shortened primary cilium length and dysregulated Sonic hedgehog signaling in Niemann-Pick C1 disease. Hum Mol Genet 2017;26:2277-89. https://doi.org/10.1093/hmg/ddx118.

[656] Vivas O, Tiscione SA, Dixon RE, Ory DS, Dickson EJ. Niemann-Pick type C disease reveals a link between lysosomal cholesterol and PtdIns(4,5)P(2) that regulates

neuronal excitability. Cell Rep 2019;27:2636-2648.e4. https://doi.org/10.1016/j.celrep.2019.04.099.

[657] Roney JC, Li SA, Farfel-Becker T, Huang N, Sun T, Xie YX, et al. Lipid-mediated motor-adaptor sequestration impairs axonal lysosome delivery leading to autophagic stress and dystrophy in Niemann-Pick type C. Dev Cell 2021;56. https://doi.org/10.1016/j.devcel.2021.03.032. 1452-+.

[658] Guix FX, Capitan AM, Casadome-Perales A, Palomares-Perez I, del Castillo IL, Miguel V, et al. Increased exosome secretion in neurons aging in vitro by NPC1-mediated endosomal cholesterol buildup. Life Sci Allianc 2021;4. https://doi.org/10.26508/a.s.202101055.

[659] Li H, Repa JJ, Valasek MA, Belroy EP, Turley SD, German DC, et al. Molecular, anatomical, and biochemical events associated with spherogeneration in mice with Niemann-Pick type C disease. J.Neuropathol.Exp.Neurol. 2005;64:323-33.

[660] Yu W, Gong JS, Ko M, Garver WS, Yanagisawa K, Michikawa M. Altered cholesterol metabolism in Niemann-Pick type C1 mouse brains affects mitochondrial function. J.Biol.Chem. 2005;280:11731-9.

[661] Fernandez A, Llacuna L, Fernandez-Checa JC, Colell A. Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. J.Neurosci. 2009;29:6394-405.

[662] Ordonez MP, Roberts EA, Kidwell CU, Yuan SH, Plaisted WC, Goldstein LS. Disruption and therapeutic rescue of autophagy in a human neuronal model of Niemann Pick type C1. Hum.Mol.Genet. 2012;21:2651-62. https://doi.org/10.1093/hmg/dds090.

[663] Camoletto PG, Vara H, Morando L, Connell E, Marletto FP, Giustetto M, et al. Synaptic vesicle docking: sphingosine regulates Syntaxin1a expression with Munc18. PloS One 2009;4:e5310. https://doi.org/10.1371/journal.pone.0005310.

[664] Arroyo AI, Camoletto PG, Morando L, Sassoe-Pognetto M, Giustetto M, Van Veldhoven PP, et al. Pharmacological reversion of sphingomyelin-induced dendritic spine anomalies in a Niemann Pick disease type A mouse model. EMBO Mol Med 2014;6:398-413. https://doi.org/10.1002/emmm.201302649.

[665] Walkley SU. Pyramidal neurons with ectopic dendrites in storage diseases exhibit increased GM2 ganglioside immunoreactivity. Neuroscience 1995;68:1027-35.

[666] March PA, Thrall MA, Brown DE, Mitchell TW, Lowenthal AC, Walkley SU. GABAergic neuroaxonal dystrophy and other cytopathological alterations in feline Niemann-Pick disease type C. Acta Neuropathol (Berl) 1997;94:164-72.

[667] Karten B, Vance DE, Campenot RB, Vance JE. Trafficking of cholesterol from cell bodies to distal axons in Niemann Pick C1-deficient neurons. J Biol Chem 2003;278:4168-75.

[668] Karten B, Campenot RB, Vance DE, Vance JE. The Niemann-Pick C1 protein in recycling endosomes of presynaptic nerve terminals. J Lipid Res 2006;47:504-14.

[669] Wasser CR, Ertunc M, Liu X, Kavalaki ET. Cholesterol-dependent balance between evoked and spontaneous synaptic vesicle recycling. J.Physiol 2007;579:413-29.

[670] Hawes CM, Wiemer H, Krueger SR, Karten B. Pre-synaptic defects of NPC1-deficient hippocampal neurons are not directly related to plasma membrane cholesterol. J.Neurochem. 2010;114:311-22.

[671] Xu S, Zhou S, Xia D, Xia J, Chen G,uan S, et al. Defects of synaptic vesicle turnover at excitatory and inhibitory synapses in Niemann-Pick C1-deficient neurons. Neuroscience 2010;167:608-20.

[672] Zhou SY, Xu SJ, Yan YG, Yu HM, Ling SC, Luo JH. Decreased purinergic inhibition of synaptic activity in a mouse model of Niemann-Pick disease type C. Hippocampus 2011;21:212-9.

[673] Buard I, Pfrieger FW. Relevance of neuronal and glial NPC1 for synaptic input to cerebellar Purkinje cells. Mol Cell Neurosci 2014;61:65-71. https://doi.org/10.1016/j.mcn.2014.06.003.

[674] Yan X, Ma L, Hovakimyan M, Lukas J, Wree A, Frank M, et al. Defects in the retina of Niemann-pick type C1 mutant mice. BMC Neurosci 2014;15:126.

[675] Mitroi DN, Pereyra-Gómez G, Soto-Huelin B, Senovilla F, Kobayashi T, Esteban JA, et al. NPC1 enables cholesterol mobilization during long-term potentiation that can be restored in Niemann-Pick disease type C by CYP4A61 activation. EMBO Rep 2019;20:e48143. https://doi.org/10.15252/embr.201948143.

[676] Tiscione SA, Vivas O, Ginsburg KS, Bers DM, Ory DS, Santana LF, et al. Disease-associated mutations in Niemann-Pick type C1 alter ER calcium signaling and neuronal plasticity. J Cell Biol 2019;218:4141-56. https://doi.org/10.1083/jcb.201903018.

[677] Gabande-Rodriguez E, Boya P, Labrador V, Dotti CG, Ledesma MD. High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A. Cell Death Differ 2014;21:864-75. https://doi.org/10.1038/cdd.2014.4.

[678] Sarkar S, Carroll B, Buganim Y, Maetzel D, Ng AH, Cassady JP, et al. Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease. Cell Rep 2013;5:1302-15. https://doi.org/10.1016/j.celrep.2013.10.042.

[679] Gurda BL, Bagel JH, Fisher SJ, Schultz ML, Lieberman AP, Hand P, et al. LC3 immunostaining in the inferior olivary nuclei of cats with Niemann-Pick disease type C1 is associated with patterned Purkinje cell loss. J Neuropathol Exp Neurol 2018;77:229-45. https://doi.org/10.1093/jnen/nlx119.

[680] Ginzburg L, Futerman AH. Defective calcium homeostasis in the cerebellum in a mouse model of Niemann-Pick A disease. J Neurochem 2005;95:1619-28. https://doi.org/10.1111/j.1471-4159.2005.03534.x.

[681] Tiscione SA, Casas M, Horvath JD, Lam V, Hino K, Ory DS, et al. IP(3)R-driven increases in mitochondrial Ca(2+) promote neuronal death in NPC disease. Proc Natl Acad Sci U S A 2021;118:e2110629118. https://doi.org/10.1073/pnas.21106291118.

[682] Marin T, Dulcey AE, Campos F, de la Fuente C, Acuna M, Castro J, et al. c-Abl activation linked to autophagy-lysosomal dysfunction contributes to neurological
impairment in Niemann-Pick type A disease. Front Cell Dev Biol 2022:10. https://doi.org/10.3389/fcell.2022.844297.

[683] Alvarez AR, Klein A, Castro J, Cancino GI, Amigo J, Mosqueira M, et al. Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease. FASEB J 2008;22:3617-27.

[684] Contreras PS, Tapia PJ, Gonzalez-Hodar L, Peluso I, Soldati C, Napolitano G, et al. c-Abl inhibition activates TFEB and promotes cellular clearance in a lysosomal disorder. Iscience 2020;23. https://doi.org/10.1016/j.isci.2020.101691.

[685] Pérez-Canamás A, Benvegnù S, Rueda CB, Rábano A, Satrústegui J, Ledesma MD. Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann-Pick disease. Mol Psychiatry 2017; 22:711-23. https://doi.org/10.1038/np.2016.148.

[686] Klein A, Maldonado C, Vargas LM, Gonzalez M, Robledo F, de Arce KP, et al. Oxidative stress activates the c-Abl/p73 proapoptotic pathway in Niemann-Pick type C neurons. Neurobiol Dis 2011;41:209-18. https://doi.org/10.1016/j.nbd.2010.09.008.

[687] Kennedy BE, LeBlanc VG, Mailman TM, Fice D, Burton I, Karakach TK, et al. Pre-symptomatic activation of antioxidant responses and alterations in glucose and pyruvate metabolism in Niemann-Pick Type C1-deficient murine brain. PloS One 2013;8. https://doi.org/10.1371/journal.pone.0082685. e82685-e82685.

[688] Oddi S, Caporali P, Dragotto J, Totaro A, Maiolati M, Scipioni L, et al. The endocannabinoid system is affected by cholesterol dyshomeostasis: Insights from a murine model of Niemann Pick type C disease. Neurobiol Dis 2019:130. https://doi.org/10.1016/j.nbd.2019.104531.

[689] Bartoll A, Toledano-Zaragoza A, Casas J, Guzmán M, Schuchman EH, Ledesma MD. Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling. EMBO Mol Med 2020;12:e11776. https://doi.org/10.15252/emm.201911776.

[690] Buccinna B, Piccinini M, Prinetti A, Scandroglio F, Prioni S, Valsecchi M, et al. Alterations of myelin-specific proteins and sphingolipids characterize the brains of acid sphingomyelinase-deficient mice, an animal model of Niemann-Pick disease type A. J Neurochem 2009;109:105-15. https://doi.org/10.1111/j.1471-4159.2009.05947.x.

[691] Palmeri S, Battisti C, Federico A, Guazzi GC. Hypoplasia of the corpus callosum in Niemann-Pick type-C disease. Neuroradiology 1994;36:20-2. https://doi.org/10.1007/bf00599187.

[692] Higashi Y, Murayama S, Pentchev PG, Suzuki K. Peripheral-nerve pathology in Niemann-Pick type-C mouse. Acta Neuropathol 1995;90:158-63.

[693] Weintraub H, Abramovici A, Sandbank U, Pentchev PG, Brady RO, Sekine M, et al. Neurological mutation characterized by dysmyelination in NCTR-BALB/C mouse with lysosomal lipid storage disease. J Neurochem 1985;45:665-72. https://doi.org/10.1111/j.1471-4159.1985.tb04044.x.

[694] Xie CL, Burns DK, Turley SD, Dietsch JM. Cholesterol is sequestered in the brains of mice with Niemann-Pick type C disease but turnover is increased. J Neuropathol Exp Neurol 2000;59:1106-17. https://doi.org/10.1093/jnen/59.12.1106.

[695] Lope-Piedrafita S, Totenhagen JW, Hicks CM, Erickson RP, Trouard TP. MRI detects therapeutic effects in weanling Niemann-Pick type C mice. J Neurosci Res 2008;86:2802-7. https://doi.org/10.1002/jnr.21707.

[696] Yan X, Lukas J, Witt M, Wree A, Hubner R, Frech M, et al. Decreased expression of myelin gene regulatory factor in Niemann-Pick type C1 mouse. Metab Brain Dis 2011;26:299-306.

[697] Bagel JH, Sikora TU, Prociuk M, Pesayco JP, Mizisin AP, Shelton GD, et al. Electrodiagnostic testing and histopathologic changes confirm peripheral nervous system myelin abnormalities in the feline model of niemann-pick disease type C. J Neuropath Exp Neurol 2013;72:256-62. https://doi.org/10.1097/NEN.0b013e318286587f.

[698] Yu T, Lieberman AP. NPC1 acting in neurons and glia is essential for the formation and maintenance of CNS myelin. PLoS Genet 2013;9:e1003462. https://doi.org/10.1371/journal.pgen.1003462.

[699] Yang F, Feng X, Rolfs A, Luo J. Lovastatin promotes myelin formation in NPC1 mutant oligodendrocytes. J Neurol Sci 2018;386:56-63. https://doi.org/10.1016/j.jns.2018.01.015.

[700] De Nuccio C, Bernardo A, Ferrante A, Pepponi R, Martire A, Falchi M, et al. Adenosine A(2A) receptor stimulation restores cell functions and differentiation in Niemann-Pick type C-like oligodendrocytes. Sci Rep 2019;9:9782. https://doi.org/10.1038/s41598-019-46268-8.

[701] Yang F, Guan YD, Feng X, Rolfs A, Schlüter H, Luo JK. Proteomics of the corpus callosum to identify novel factors involved in hypomyelinated Niemann-Pick type C disease mice. Mol Brain 2019:12. https://doi.org/10.1186/s13041-019-0440-9.

[702] Angelini R, Yutuc E, Wyatt MF, Newton J, Yusuf FA, Griffiths L, et al. Visualizing cholesterol in the brain by on-tissue derivatization and quantitative mass spectrometry imaging. Anal Chem 2021;93:4932-43. https://doi.org/10.1021/acs.analchem.0c05399.

[703] Weintraub H, Abramovici A, Amichai D, Eldar T, Bendor L, Pentchev PG, et al. Morphometric studies of pancreatic acinar granule formation in NCTR-BALB/C mice. J Cell Sci 1992:102:141-7.

[704] Munzer P, Borst O, Walker B, Schmid E, Feijge MAH, Cosemans J, et al. Acid sphingomyelinase regulates platelet cell membrane scrambling, secretion, and thrombus formation. Arterioscler Thromb Vasc Biol 2014;34. https://doi.org/10.1161/atvbaha.112.300210. 61+.

[705] Xu J, Dang YJ, Ren YRZ, Liu JO. Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci U S A 2010;107:4764-9. https://doi.org/10.1073/pnas.0910872107.

[706] Rahit K, Tarailo-Graovac M. Genetic modifiers and rare mendelian disease. Genes 2020:11. https://doi.org/10.3390/genes11030239.

[707] Hassan S, Sidransky E, Tayebi N. The role of epigenetics in lysosomal storage disorders: Uncharted territory. Mol Genet Metab 2017;122:10-8. https://doi.org/10.1016/j.ymgme.2017.07.012.

[708] Jakobkiewicz-Banecka J, Gabig-Ciminska M, Banecka-Majkutewicz Z, Banecki B, Wegrzyn A, Wegrzyn G. Factors and processes modulating phenotypes in neuronopathic lysosomal storage diseases. Metab Brain Dis 2014;29:1-8. https://doi.org/10.1007/s11011-013-9455-6.

[709] Miyawaki S, Yoshida H, Mitsuoka S, Enomoto H, Ikehara S. A mouse model for Niemann-Pick disease. influence of genetic background on disease expression in spm/spm mice. J Hered 1986;77:379-84. https://doi.org/10.1093/oxfordjournals.jhered.a110265.

[710] Zhang J, Erickson RP. A modifier of Niemann Pick C 1 maps to mouse chromosome 19. Mamm Genome 2000;11:69-71. https://doi.org/10.1007/s003350010013.

[711] Parra J, Klein AD, Castro J, Morales MG, Mosqueira M, Valencia I, et al. NPC1 deficiency in the C57BL/6J genetic background enhances Niemann-Pick disease type C spleen pathology. Biochem Biophys Res Commun 2011;413:400-6. https://doi.org/10.1016/j.bbrc.2011.08.096.

[712] Marshall CA, Watkins-Chow DE, Palladino G, Deutsch G, Chandran K, Pavan WJ, et al. In Niemann-Pick C1 mouse models, glial-only expression of the normal gene extends survival much further than do changes in genetic background or treatment with hydroxypropyl-beta-cyclodextrin. Gene 2018;643:117-23. https://doi.org/10.1016/j.gene.2017.12.006.

[713] Elleder M, Cihula J. Niemann-Pick disease (variation in the sphingomyelinase deficient group). Eur J Pediatr 1983;140:323-8. https://doi.org/10.1007/BF00442673.

[714] Vanier MT, Wender DA, Comly ME, Rousson R, Brady RO, Pentchev PG. Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification: A collaborative study on 70 patients. Clin Genet 1988; 33:331-48. https://doi.org/10.1111/j.1399-0004.1988.tb03460.x.

[715] Moreno R, Lardennois C, Drouin-Garraud V, Verspyck E, Marret S, Laquerrière A. Prenatal revelation of Niemann-Pick disease type C in siblings. Acta Paediatr 2008;97:1136-9. https://doi.org/10.1111/j.1651-2227.2008.00829.x.

[716] Walterfang M, Fietz M, Abel L, Bowman E, Mocellin R, Velakoulis D. Gender dimorphism in siblings with schizophrenia-like psychosis due to Niemann-Pick disease type C. J Inherit Metab Dis 2009;32:S221-6. https://doi.org/10.1007/s10545-009-1173-1.

[717] Anheim M, Lagha-Boukbiza O, Fleury-Lesaunier MC, Valenti-Hirsch MP, Hirsch E, Gervais-Bernard H, et al. Heterogeneity and frequency of movement disorders in juvenile and adult-onset Niemann-Pick C disease. J Neurol 2014;261:174-9. https://doi.org/10.1007/s00415-013-7159-9.

[718] Benussi A, Alberici A, Premi E, Bertasi V, Cotelli MS, Murate T, Sarna JUR, et al. Phenotypic heterogeneity of Niemann-Pick disease type C in monozygotic twins. J Neurol 2015;262:642-7. https://doi.org/10.1007/s00415-014-7619-x.

[719] Soliani L, Salerno GG, Pisani F, Barigazzi I, Rizzi S, Spagnoli C, et al. Neuropsychological and behavioral disorders as presentation symptoms in two brothers with early-infantile Niemann-Pick type C. Acta Biomed 2020;91: e2020075. https://doi.org/10.23750/abm.v9i13.9727.

[720] Pass T, Wiesner RJ, Pla-Martin D. Selective neuron vulnerability in common and rare diseases-mitochondria in the focus. Front Mol Biosci 2021:8. https://doi.org/10.3389/fmolb.2021.676187.

[721] Terada N, Banno Y, Ohno N, Fujii Y, Murate T, Sarna JUR, et al. Compartmentation of the mouse cerebellar cortex by sphingosine kinase. J Comp Neurol 2004;469:119-27. https://doi.org/10.1002/cne.11002.

[722] Pascua-Maestro R, Corraliza-Gomez M, Fadrique-Rojo C, Ledesma MD, Schuchman EH, Sanchez D, et al. Apolipoprotein D-mediated preservation of lysosomal function promotes cell survival and delays motor impairment in Niemann-Pick type A disease. Neurobiol Dis 2020;144:105046. https://doi.org/10.1016/j.nbd.2020.105046.

[723] Pacheco CD, Elrick MJ, Lieberman AP. Tau deletion exacerbates the phenotype of Niemann-Pick type C mice and implicates autophagy in pathogenesis. Hum Mol. Genet. 2009;18:956-65.

[724] Smith AF, Vanderah TW, Erickson RP. Haploinsufficiency of tau decreases survival of the mouse model of Niemann-Pick disease type C1 but does not alter tau phosphorylation. J Appl Genet 2020. https://doi.org/10.1007/s13353-020-00572-6.

[725] Nunes A, Pressey SNR, Cooper JD, Soriano S. Loss of amyloid precursor protein in a mouse model of Niemann-Pick type C disease exacerbates its phenotype and disrupts tau homeostasis. Neurobiol Dis 2011;42:349-59. https://doi.org/10.1016/j.nbd.2011.01.028.

[726] Sun Y, Ishibashi M, Seimon T, Lee M, Sharma SM, Fitzgerald KA, et al. Free cholesterol accumulation in macrophage membranes activates toll-like receptors and p38 mitogen-activated protein kinase and induces cathepsin K. Circ Res 2009; 104:455-U75. https://doi.org/10.1161/circresaha.108.182568.

[727] Fu R, Yanjanin NM, Elrick MJ, Ware C, Lieberman AP, Porter FD. Apolipoprotein E genotype and neurological disease onset in Niemann-Pick disease, type C1. Am J Med Genet A 2012;158A:2775-80. https://doi.org/10.1007/ajmg.a.35395.

[728] Lee H, Lee JK, Bae YC, Yang SH, Okino N, Schuchman EH, et al. Inhibition of GM3 sphingosine attenuates neuropathology of Niemann-Pick disease type C, by affecting sphingolipid metabolism. Mol Cells 2014;37:161-71. https://doi.org/10.14348/molcells.2014.2347.

[729] Wheeler S, Haberkant P, Bhardwaj M, Tongue P, Ferraz MJ, Halter D, et al. Cytosolic glucosylceramide regulates endolysosomal function in Niemann-Pick disease.
type C disease. Neurobiol Dis 2019;127:242-52. https://doi.org/10.1016/j.
ndb.2019.03.005.

[730] Chung C, Elrick MJ, Dell'Orco JM, Qin ZS, Kalyana-Sundaram S, Chinnaiyan AM, et al. Heat shock protein beta-1 modifies anterior to posterior purkinje cell vulnerability in a mouse model of Niemann-Pick type C disease. PLoS Genet 2016; 12:e1006042. https://doi.org/10.1371/journal.pgen.1006042.

[731] Pugach EK, Feltes M, Kaufman R, Ory DS, Bang AG. High-content screen for modifiers of Niemann-Pick type C disease in patient. Hum Mol Genet 2018; 27:2101-12. https://doi.org/10.1093/hmg/ddy117.

[732] Coughnou A, Fellmeth M, Gu T, Davidson CD, Gibson AL, Pavan WJ, et al. Maternal immune activation modifies the course of Niemann-pick disease, type C1 in a gender specific manner. Mol Genet Metab 2020;129:165-70. https://doi.org/10.1016/j.ymgme.2019.10.004.

[733] Martin KB, Williams IM, Cluzeau CV, Coughnou A, Dale RK, Iben JR, et al. Identification of novel pathways associated with patterned cerebellar purkinje neuron degeneration in Niemann-Pick disease, type C1. Int J Mol Sci 2020;21: https://doi.org/10.3390/ijms21010292.

[734] Liu EA, Schultz ML, Mochida C, Chung C, Paulson HL, Lieberman AP. Fbxo2 mediates clearance of damaged lysosomes and modifies neurodegeneration in the Niemann-Pick C brain. JCI. Insight 2020. https://doi.org/10.1172/jci.
insight.136676.

[735] Meneses-Salas E, Garcia-Forn M, Castany-Pladevall C, Lu A, Fajardo A, Jose J, et al. Lack of annexin A6 exacerbates liver dysfunction and reduces lifespan of Niemann-Pick type C protein-deficient mice. Am J Pathol 2021;191:475-86. https://doi.org/10.1152/ajpgi.00124.2020.

[736] Lopez AM, Jones RD, Repa JJ, Turley SD. Niemann-Pick C1-deficient mice lacking sterol O-acyltransferase 2 have less hepatic cholesterol entrapment and improved liver function. Am J Physiol Gastrointest Liver Physiol 2018;315:G454-g463. https://doi.org/10.1152/ajpgi.00124.2018.

[737] Rogers MA, Chang CCY, Maue RA, Melton EM, Peden AA, Garver WS, et al. Acat1/Soat1 knockout extends the mutant NanclPcn1 mouse lifespan and ameliorates functional deficiencies in multiple organellae of mutant mice. Proc Natl Acad Sci U S A 2022;119:e2201646119. https://doi.org/10.1073/pnas.2201646119.

[738] Bernardo A, Malara M, Bertuccini L, De Nuccio C, Visentin S, Minghetti L. The antihypertensive drug telmisartan protects oligodendrocytes from cholesterol accumulation and promotes differentiation by a PPAR-gamma-mediated mechanism. Int J Mol Sci 2021;22: https://doi.org/10.3390/ijms22179434.

[739] Cawley NX, Lyons AT, Abebe D, Luke R, Yerger J, Telese R, et al. Complex N-linked glycosylation: a potential modifier of Niemann-Pick disease, type C1 pathology. Int J Mol Sci 2022;23:5082.

[740] Schneede A, Schmidt CK, Holtta-Vuori M, Heeren J, Willenborg M, Blanz J, et al. Role for LAMP-2 in endosomal cholesterol transport. J Cell Mol Med 2011;15: 280-95. https://doi.org/10.1111/j.1582-4934.2009.00973.x.

[741] Li J, Pfeffer SR. Lysosomal membrane glycoproteins bind cholesterol and contribute to lysosomal cholesterol export. Elife 2016:5. https://doi.org/
10.7554/eLife.21635.

[742] Heybrock S, Kanerva K, Meng Y, Ing C, Liang A, Xiong ZJ, et al. Lysosomal integral membrane protein-2 (LIMP-2/SCARB2) is involved in lysosomal cholesterol export. Nat Commun 2019;10:3521. https://doi.org/10.1038/
s41467-019-11425-0.

[743] Perez RK, Gordon MG, Subramanian M, Kim MC, Hartoularos GC, Targ SS, et al. Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. Science 2022;376. https://doi.org/10.1126/science.abf1970. 153 +.

[744] Yazar S, Alqucira-Hernandez J, Wing K, Senabou A, Gordon MG, Andersen S, et al. Single-cell eQTL mapping identifies cell type-specific genetic control of autoimmune disease. Science 2022;376. https://doi.org/10.1126/science.
abf3041. 154 +.

[745] Bryois J, Calini D, Macnair W, Foo L, Urich E, Ortmann W, et al. Cell-type-specific cis-eQTLs in eight human brain cell types identify novel risk genes for psychiatric and neurological disorders. Nat Neurosci 2022;25:1104-12. https://doi.org/
10.1038/s41593-022-01128-z.

[746] Toledano-Zaragoza A, Ledesma MD. Addressing neurodegeneration in lysosomal storage disorders: Advances in Niemann-Pick diseases. Neuropharmacology 2020: 171. https://doi.org/10.1016/j.neuropharm.2019.107851.

[747] Daloze P, Delvin EE, Glorieux FH, Corman JL, Bettez P, Toussi T, et al. Replacement therapy for inherited human disease: Liver orthotopic transplantation in Niemann-Pick disease type A. Am J Med Genet 1977;1:229-39. https://doi.org/10.1002/ajmg.1320010209.

[748] Jin HK, Carter JE, Huntley GW, Schuchman EH. Intracerebral transplantation of mesenchymal stem cells into an acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. J Clin Invest 2002;109:1183-91. https://doi.org/10.1072/jci200214862.

[749] Jin HK, Schuchman EH. Ex vivo gene therapy using bone marrow-derived cells: Combined effects of intracerebral and intravenous transplantation in a mouse model of Niemann-Pick disease. Mol Ther 2003;8:876-85. https://doi.org/
10.1016/j.ymthe.2003.07.008.

[750] Suchi M, Dinur T, Desnick RJ, Gatt S, Pereira L, Gilboa E, et al. Retroviral-mediated transfer of the human acid sphingomyelinase cDNA: correction of the metabolic defect in cultured Niemann-Pick disease cells. Proc Natl Acad Sci 1992; 89:3227-31. https://doi.org/10.1073/pnas.89.8.3227.

[751] He XX, Miranda SRP, Xiong XL, Dagan A, Gatt S, Schuchman EH. Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells. BBA-Protein Struct M 1999;1432:251-64. https://doi.org/10.1016/s0167-4838(99)00069-2.

[752] Miranda SRP, He XX, Simonaro CM, Gatt S, Dagan A, Desnick RJ, et al. Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads

to visceral, but not neurological, correction of the pathophysiology. FASEB J
2000;14:1988-95. https://doi.org/10.1096/fj.00-0014com.

[753] Yang WW, Dodge JC, Passini MA, Taksir TV, Griffiths D, Schuchman EH, et al. Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann-Pick A mouse. Exp Neurol 2007;207:258-66. https://doi.org/10.1016/j.expneurol.2007.06.017.

[754] Dodge JC, Clarke J, Treleaven CM, Taksir TV, Griffiths DA, Yang WD, et al. Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp Neurol 2009; 215:349-57. https://doi.org/10.1016/j.expneurol.2008.10.021.

[755] Muro S, Schuchman EH, Muzykantov VR. Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol Ther 2006;13:135-41. https://doi.org/10.1016/j.
ymthe.2005.07.687.

[756] Muro S, Garnacho C, Champion JA, Leferovich J, Gajewski C, Schuchman EH, et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther 2008;16:1450-8. https://doi.org/10.1038/mt.2008.127.

[757] Garnacho C, Dhami R, Simone E, Dziubla T, Leferovich J, Schuchman EH, et al. Delivery of acid sphingomyelinase in normal and Niemann-Pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers. J Pharmac Exp Ther 2008;325:400-8. https://doi.org/10.1124/
jpet.107.133298.

[758] Garnacho C, Dhami R, Solomon M, Schuchman EH, Muro S. Enhanced delivery and effects of acid sphingomyelinase by ICAM-1-targeted nanocarriers in type B Niemann-Pick disease mice. Mol Ther 2017;25:1686-96. https://doi.org/
10.1016/j.ymthe.2017.05.014.

[759] Dhami R, Schuchman EH. Mannose 6-phosphate receptor-mediated uptake is defective in acid sphingomyelinase-deficient macrophages - implications for Niemann-Pick disease enzyme replacement therapy. J Biol Chem 2004;279: 1526-32. https://doi.org/10.1074/jbc.M309465200.

[760] Rappaport J, Garnacho C, Muro S. Clathrin-mediated endocytosis is impaired in type A-B Niemann-Pick disease model cells and can be restored by ICAM-1-mediated enzyme replacement. Mol Pharm 2014;11:2887-95. https://doi.org/
10.1021/mp500241y.

[761] Murray JM, Thompson AM, Vitsky A, Hawes M, Chuang WL, Pacheco J, et al. Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency: The utility of animal models of disease in the toxicological evaluation of potential therapeutics. Mol Genet Metab 2015;114:217-25. https://doi.org/10.1016/j.
ymgme.2014.07.005.

[762] McGovern MM, Wasserstein MP, Kirmse B, Duvall WL, Schiano T, Thurberg BL, et al. Novel first-dose adverse drug reactions during a phase I trial of oludapase alfa (recombinant human acid sphingomyelinase) in adults with Niemann-Pick disease type B (acid sphingomyelinase deficiency). Genet Med 2016;18:34-40. https://doi.org/10.1038/gim.2015.24.

[763] Patterson MC, Dibiscelie AM, Higgins JJ, Abel RB, Schiffmann R, Parker CC, et al. The effect of cholesterol-lowering agents on hepatic and plasma-cholesterol in Niemann-Pick disease type C. Neurology 1993;43:61-4. https://doi.org/
10.1212/WNL.43.1 Part 1.61.

[764] Hughes AB, Rudge AJ. Deoxynojirimycin - synthesis and biological-activity. Nat Prod Rep 1994;11:135-62. https://doi.org/10.1039/np9941100135.

[765] Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldexoynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 1994;269:8362-5.

[766] Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al. Novel oral treatment of Gaucher's disease with N-butyldexoynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-5. https://doi.org/
10.1016/s0140-6736(00)02161-9.

[767] Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol 2001;11:1283-7. https://doi.org/
10.1016/s0960-9822(01)00396-7.

[768] Stein VM, Crooks A, Ding W, Prociuk M, O'Donnell P, Bryan C, et al. Miglustat improves purkinje cell survival and alters microglial phenotype in feline niemann-pick disease type C. J Neuropathol.Exp.Neurol. 2012;71:434-48.

[769] Nietupski JB, Pacheco JJ, Chuang WL, Maratea K, Li L, Foley J, et al. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice. Mol.Genet.Metab
2012;105:621-8.

[770] Ridley CM, Thur KE, Shanahan J, Thillaiappan NB, Shen A, Uhl K, et al. beta-Glucosidase 2 (GBA2) activity and imino sugar pharmacology. J Biol Chem 2013; 288:26052-66. https://doi.org/10.1074/jbc.M113.463562.

[771] Camargo F, Erickson RP, Garver WS, Hossain GS, Carbone PN, Heidenreich RA, et al. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Life Sci 2001;70:131-42. https://doi.org/10.1016/s0024-3205(01)01384-4.

[772] Griffin LD, Gong W, Verot L, Mellon SH. Niemann-Pick type C disease involves disrupted neurosteroidogenesis and responds to allopregnanolone. Nat Med 2004; 10:704-11. https://doi.org/10.1038/nm1073.

[773] Liu B, Li H, Repa JJ, Turley SD, Dietschy JM. Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J Lipid Res 2008;49:663-9.

[774] Abi-Mosleh L, Infante RE, Radhakrishnan A, Goldstein JL, Brown MS. Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells. Proc Natl Acad Sci USA 2009;106: 19316-21. https://doi.org/10.1073/pnas.0910191610.

[775] Davidson CD, Ali NF, Micsenyi MC, Stephney G, Renault S, Dobrenis K, et al. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates
neuronal cholesterol and glycosphingolipid storage and disease progression. PloS One 2009;4:e6951.

[776] Leau O, Ducrot R. Action de lacetylleucine sur le vertige experimental de la souris. Compt Rend Seances Soc Biol Ses Filiales 1957;151:1365-7.

[777] Bremova T, Malinová V, Amraoui Y, Mengel E, Reinke J, Kolníková M, et al. Acetyl-dll-leucine in Niemann-Pick type C: A case series. Neurology 2015;85: 1368-75. https://doi.org/10.1212/wnl.00000000000002041.

[778] Kaya E, Smith DA, Smith C, Morris L, Bremova-Ertl T, Cortina-Borja M, et al. Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Commun 2021;3. https://doi.org/10.1093/braincomms/SEA148.

[779] Fields T, Patterson M, Bremova-Ertl T, Belcher G, Billington I, Churchill GC, et al. A master protocol to investigate a novel therapy acetyl-l-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosides, and ataxia telangiectasia. Trials 2021;22. https://doi.org/10.1186/s13063-020- 05009-3.

[780] Churchill GC, Strupp M, Factor C, Bremova-Ertl T, Factor M, Patterson MC, et al. Acetylation turns leucine into a drug by membrane transporter switching. Sci Rep 2021;11. https://doi.org/10.1038/s41598-021-95255-5.

[781] Vigh L, Literati PN, Horvath I, Torok Z, Balogh G, Glatz A, et al. Bimocloplom: A nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nat Med 1997;3:1150-4. https://doi.org/10.1038/ nm1097-1150.

[782] Kieran D, Kalmar B, Dick JRT, Riddoch-Contreras J, Burnstock G, Greensmith L. Treatment with arimocloplom, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med 2004;10:402-5. https://doi.org/10.1038/ nm1021.

[783] Kirkegaard T, Gray J, Priestman DA, Wallom KL, Atkins J, Olsen OD, et al. Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Sci Transl Med 2016;8:355ra118. https://doi.org/10.1126/ scitranslmed.aad9823.

[784] Sakiyama T, Tsuda M, Owada M, Joh K, Miyawaki S, Kitagawa T. Bone-marrow transplantation for Niemann-Pick mice. Biochim Biophys Res Commun 1983;113: 605-10. https://doi.org/10.1016/0006-291x(83)91769-2.

[785] Smanik EJ, Tavil AS, Jacobs GH, Schaefer IA, Farquhar L, Weber FL, et al. Orthotopic liver-transplantation in 2 adults with Niemann-Pick and gauchers diseases - implications for the treatment of inherited metabolic disease. Hepatology 1993;17:42-9. https://doi.org/10.1002/hep.184017019.

[786] Vellodi A, Hobbs JR, Odonnell NM, Coulter BS, Hughjones K. Treatment of Niemann-Pick disease type-B by allogeneic bone-marrow transplantation. Br Med J 1987;295:1375-6. https://doi.org/10.1136/bmj.295.6610.1375.

[787] Bayever E, Kamani N, Ferreira P, Machin GA, Yudkoff M, Conard K, et al. Bone- marrow transplantation for Niemann-Pick type-1A disease. J Inherit Metab Dis 1992;15:919-28. https://doi.org/10.1007/bf01800234.

[788] Miranda SRP, Erlich S, Visser JWM, Gatt S, Dagan A, Friedrich VL, et al. Bone marrow transplantation in acid sphingomyelinase-deficient mice: Engraftment and cell migration into the brain as a function of radiation, age, and phenotype. Blood 1997;90:444-52.

[789] Miranda SRP, Erlich S, Friedrich VL, Gatt S, Schuchman EH. Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann-Pick disease. Gene Ther 2000;7:1768-76. https://doi.org/ 10.1038/sj.gt.3301300.

[790] Scaggiante B, Pineschi A, Sustersich M, Andolina M, Agosti E, Romeo D. Successful therapy of Niemann-Pick disease by implantation of human amniotic membrane. Transplantation 1987;44:59-61. https://doi.org/10.1097/00007890- 198707000-00014.

[791] Bembi B, Comelli M, Scaggiante B, Pineschi A, Rapelli S, Gornati R, et al. Treatment of sphingomyelinase deficiency by repeated implantations of amniotic epithelial-cells. Am J Med Genet 1992;44:527-33. https://doi.org/10.1002/ ajmg.132044034.

[792] Sidman RL, Li JX, Stewart GR, Clarke J, Yang W, Snyder EY, et al. Injection of mouse and human neural stem cells into neonatal Niemann-Pick A model mice. Brain Res 2007;1140:195-204. https://doi.org/10.1016/j.brainres.2007.01.011.

[793] Barbon CM, Ziegler RJ, Li C, Armentano D, Cherry M, Desnick RJ, et al. AAV8- Mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease. Mol Ther 2005;12:431-40. https://doi.org/10.1016/j.ymthe.2005.03.011.

[794] Passini MA, Macauley SL, Huff MR, Taksir TV, Bu J, Wu IH, et al. AAV vector- mediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol Ther 2005;11:754-62. https://doi.org/10.1016/j. ymthe.2005.01.011.

[795] Dodge JC, Clarke J, Song A, Bu J, Yang WD, Taksir TV, et al. Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease. Proc Natl Acad Sci U S A 2005;102: 17822-7. https://doi.org/10.1073/pnas.0509062102.

[796] Bu J, Ashe KM, Bringas J, Marshall J, Dodge JC, Cabrera-Salazar MA, et al. Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A. Mol Ther 2012;20:1893-901. https://doi.org/ 10.1038/mt.2012.118.

[797] Samaranch L, Perez-Canamas A, Soto-Huelin B, Sudhakar V, Jurado-Arjona J, Hadaczek P, et al. Adeno-associated viral vector serotype 9-based gene therapy for Niemann-Pick disease type A. Sci Transl Med 2019;11. https://doi.org/ 10.1126/scitranslmed.aat3738.

[798] Ziegler RJ, Brown C, Barbon CM, D'Angona AM, Schuchman EH, Andrews L, et al. Pulmonary delivery of recombinant acid sphingomyelinase improves clearance of lysosomal sphingomyelin from the lungs of a murine model of Niemann-Pick disease. Mol Genet Metab 2009;97:35-42. https://doi.org/10.1016/j. ymgme.2009.01.008.

[799] Wasserstein MP, Jones SA, Soran H, Diaz GA, Lippa N, Thurberg BL, et al. Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency. Mol Genet Metab 2015;116:88-97. https://doi.org/ 10.1016/j.ymgme.2015.05.013.

[800] Thurberg BL, Wasserstein MP, Jones SA, Schianzo TD, Cox GF, Puga AC. Clearance of hepatic sphingomyelin by olipudase alfa is associated with improvement in lipid profiles in acid sphingomyelinase deficiency. Am J Surg Pathol 2016;40: 1232-42. https://doi.org/10.1097/pas.0000000000000659.

[801] Wasserstein MP, Diaz GA, Lachmann RH, Jouvin MH, Nandy I, Ji AJ, et al. Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months. J Inherit Metab Dis 2018;41:829-38. https://doi.org/10.1007/s10545-017-0123-6.

[802] Thurberg BL, Diaz GA, Lachmann RH, Schiano T, Wasserstein MP, Ji AJ, et al. Long-term efficacy of olipudase alfa in adults with acid sphingomyelinase deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro- and anti-atherogenic lipid profiles after 42 months of treatment. Mol Genet Metab 2020;131:245-52. https://doi.org/ 10.1016/j.ymgme.2020.06.010.

[803] Diaz GA, Giugliani R, Guffon N, Jones SA, Mengel E, Scarpa M, et al. Long-term safety and clinical outcomes of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency: two-year results. Orphanet J Rare Dis 2022;17. https://doi.org/10.1186/s13023-022-02587-0.

[804] Wasserstein M, Lachmann R, Hollak C, Arash-Kaps L, Barbato A, Gallagher RC, et al. A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results. Genet Med 2022. https://doi.org/10.1016/j. gim.2022.03.021.

[805] Trovò L, Stroobants S, D'Hooze R, Ledesma MD, Dotti CG. Improvement of biochemical and behavioral defects in the Niemann-Pick type A mouse by intraventricular infusion of MARCKS. Neurobiol Dis 2015;73:319-26. https://doi. org/10.1016/j.nbd.2014.09.008.

[806] Schultz M, Fawaz MV, Azaria RD, Hollon TC, Liu EA, Kunkel TJ, et al. Synthetic high-density lipoprotein nanoparticles for the treatment of Niemann-Pick diseases. BMC Med 2019;17:200. https://doi.org/10.1186/s12916-019-1423-5.

[807] Erickson RP, Garver WS, Camargo F, Hossain GS, Heidenreich RA. Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann-Pick C mice. J Inherit Metab Dis 2000;23:54-62. https://doi.org/10.1023/a:1005650933030.

[808] Reid PC, Lin S, Vanier MT, Ohno-Iwashita Y, Harwood HJ, Hickey WE, et al. Partial blockage of sterol biosynthesis with a quaternary synthase inhibitor in early postnatal Niemann-Pick type C NPC(nih) null mice brains reduces neuronal cholesterol accumulation, abrogates astrogliosis, but may inhibit myelin maturation. J Neurosci Methods 2008;168:15-25. https://doi.org/10.1016/j. jneumeth.2007.09.002.

[809] Somers KL, Brown DE, Fulton R, Schultheiss PC, Hamar D, Smith MO, et al. Effects of dietary cholesterol restriction in a feline model of Niemann-Pick type C disease. J Inherit Metab Dis 2001;24:427-36. https://doi.org/10.1023/a: 1010588112003.

[810] Liu B, Turley SD, Burns DK, Miller AM, Repa JJ, Dietschy JM. Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the NPC1-/- mouse. Proc Natl Acad Sci USA 2009;106: 2377-82.

[811] Ramirez CM, Liu B, Taylor AM, Repa JJ, Burns DK, Weinberg AG, et al. Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life. Pediatr. Res. 2010;68:309-15.

[812] Rosenbaum AI, Zhang G, Warren JD, Maxfield FR. Endocytosis of beta- cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells. Proc Natl Acad Sci USA 2010;107:5477-82.

[813] Aqul A, Liu B, Ramirez CM, Pieper AA, Estill SJ, Burns DK, et al. Unesterified cholesterol accumulation in late endosomes/lysosomes causes neurodegeneration and is prevented by driving cholesterol export from this compartment. J.Neurosci. 2011;31:9404-13. https://doi.org/10.1523/JNEUROSCI.1317-11.2011.

[814] Vite CH, Bagel JH, Swain GP, Prociuk M, Sikora TU, Stein VM, et al. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease. Sci Transl Med 2015;7:276ra26.

[815] Ory DS, Ottinger EA, Farhat NY, King KA, Jiang X, Weissfeld L, et al. Intrathecal 2-hydroxypropyl-p-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet 2017;390:1758-68. https://doi.org/10.1016/s0140-6736(17)31465-4.

[816] Farmer CA, Thurm A, Farhat N, Bianconi S, Keener LA, Porter FD. Long-term neuropsychological outcomes from an open-label phase I/IIa trial of 2-hydroxy- propyl-beta-cyclodextrins (VTS-270) in Niemann-Pick disease, type C1. CNS Drugs 2019;33:677-83. https://doi.org/10.1007/s40263-019-00642-2.

[817] Hastings C, Vieira C, Liu B, Bascon C, Gao C, Wang RY, et al. Expanded access with intravenous hydroxypropyl-beta-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis. Orphanet J Rare Dis 2019;14. https://doi.org/10.1186/s13023-019-1207-1.

[818] Hastings C, Liu B, Hurst C, Cox GF, Hrynkow S. Intravenous 2-hydroxypropyl- beta-cyclodextrin (Trapspol Cyclo) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: results of a phase 1 trial. Mol Genet Metab 2022;137:309-19. https://doi.org/10.1016/j.ymgme.2022.10.004.
[819] Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 2007;6: 765-72.

[820] Patterson MC, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C, et al. Long-term miglustat therapy in children with Niemann-Pick disease type C. J Child Neurol 2010;25:300-5. https://doi.org/10.1177/0883073809344222.

[821] Wraith JE, Vecchio D, Jacklin E, Abel L, Chadha-Boreham H, Luzy C, et al. Miglustat in adult and juvenile patients with Niemann Pick disease type C: long-term data from a clinical trial. Mol Genet Metab 2010;99:351-7. https://doi.org/10.1016/j.ymgme.2009.12.006.

[822] Fecarotta S, Romano A, Della Casa R, Del Giudice E, Bruschini D, Mansi G, et al. Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C. Orphanet J Rare Dis 2015;10:22. https://doi.org/10.1186/s13023-015-0240-y.

[823] Patterson MC, Garver WS, Giugliani R, Imrie J, Jahnova H, Meaney FJ, et al. Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study. J Inherit Metab Dis 2020;43:1060-9. https://doi.org/10.1002/jimd.12245.

[824] Erickson RP, Bernard O. Studies on neuronal death in the mouse model of Niemann-Pick C disease. J Neurosci Res 2002;68:738-44. https://doi.org/10.1002/jnr.10257.

[825] Choudhury A, Dominguez M, Puri V, Sharma DK, Narita K, Wheatley CL, et al. Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J Clin Invest 2002;109: 1541-50. https://doi.org/10.1172/jci15420.

[826] Bascunan-Castillo EC, Erickson RP, Howison CM, Hunter RJ, Heidenreich RH, Hicks C, et al. Tamoxifen and vitamin E treatments delay symptoms in the mouse model of Niemann-Pick C. J Appl Genet 2004;45:461-7.

[827] Xu M, Liu K, Swaroop M, Porter FD, Sidhu R, Firnkes S, et al. δ-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders. J Biol Chem 2012;287:39349-60. https://doi.org/10.1074/jbc. M112.357707.

[828] Marín T, Contreras P, Castro JF, Chamorro D, Balboa E, Bosch-Morató M, et al. Vitamin E dietary supplementation improves neurological symptoms and decreases c-Abl/p73 activation in Niemann-Pick C mice. Nutrients 2014;6: 3000-17. https://doi.org/10.3390/nu6083000.

[829] Langmade SJ, Gale SE, Frolov A, Mohri I, Suzuki K, Mellon SH, et al. Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease. Proc Natl Acad Sci U S A 2006;103:13807-12. https://doi.org/10.1073/pnas.0606218103.

[830] Repa JJ, Li H, Frank-Cannon TC, Valasek MA, Turley SD, Tansey MG, et al. Liver X receptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J Neurosci. 2007; 27:14470-80.

[831] Pagler TA, Neuhofer A, Laggner H, Strobl W, Stangl H. Cholesterol efflux via HDL resecretion occurs when cholesterol transport out of the lysosome is impaired. J Lipid Res 2007;48:2141-50. https://doi.org/10.1194/jlr.M700056-JLR200.

[832] Pipalia NH, Cosner CC, Huang A, Chatterjee A, Bourbon P, Farley N, et al. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc Natl Acad Sci U S A 2011; 108:5620-5. https://doi.org/10.1073/pnas.1014890108.

[833] Newton J, Hait NC, Maceyka M, Colaco A, Maczis M, Wassif CA, et al. FTY720/ fingolimod increases NPC1 and NPC2 expression and reduces cholesterol and sphingolipid accumulation in Niemann-Pick type C mutant fibroblasts. FASEB J 2017;31:1719-30. https://doi.org/10.1096/fj.201601041R.

[834] Ahmad I, Hunter RE, Flax JD, Snyder EY, Erickson RP. Neural stem cell implantation extends life in Niemann-Pick C1 mice. J Appl Genet 2007;48: 269-72. https://doi.org/10.1007/bf03195222.

[835] Bae JS, Han HS, Youn DH, Carter JE, Modo M, Schuchman EH, et al. Bone marrow-derived mesenchymal stem cells promote neuronal networks with functional synaptic transmission after transplantation into mice with neurodegeneration. Stem Cells 2007;25:1307-16. https://doi.org/10.1634/stemcells.2006-0561.

[836] Bae JS, Carter JE, Jin HK. Adipose tissue-derived stem cells rescue Purkinje neurons and alleviate inflammatory responses in Niemann-Pick disease type C mice. Cell Tissue Res 2010;340:357-69. https://doi.org/10.1007/s00441-010- 0942-3.

[837] Lee H, Bae JS, Jin HK. Human umbilical cord blood-derived mesenchymal stem cells improve neurological abnormalities of Niemann-Pick type C mouse by modulation of neuroinflammatory condition. J Vet Med Sci 2010;72:709-17. https://doi.org/10.1292/jvms.09-0495.

[838] Zhang M, Hallows JL, Wang X, Bu B, Wang W, Vincent I. Mitogen-activated protein kinase activity may not be necessary for the neuropathology of Niemann- Pick type C mice. J Neurochem 2008;107:814-22. https://doi.org/10.1111/j.1471-4159.2008.05657.x.

[839] Chevallier J, Chamoun Z, Jiang GW, Prestwich G, Sakai N, Matile S, et al. Lysobisphosphatidic acid controls endosomal cholesterol levels. J Biol Chem 2008;283:27871-80. https://doi.org/10.1074/jbc.M801463200.

[840] Moreau D, Vacca F, Vossio S, Colaco A, Paz Montoya J, et al. Drug- induced increase in lysobisphosphatidic acid reduces the cholesterol overload in Niemann-Pick type C cells and mice. EMBO Rep 2019;20:e47055. https://doi. org/10.15252/embr.201847055.

[841] Ilnyska O, Jeziorek M, Lai K, Altan-Bonnet N, Dobrowolski R, Storch J. Lysobisphosphatidic acid (LBPA) enrichment promotes cholesterol egress via exosomes in Niemann Pick type C1 deficient cells. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158916. https://doi.org/10.1016/j.bbalip.2021.158916.

[842] Alvarez AR, Klein A, Castro J, Cancino GI, Amigo J, Mosqueira M, et al. Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease. FASEB J 2008;22:3617-27. https://doi.org/10.1096/fj.07-102715.

[843] Borbon IA, Hillman Z, Duran Jr E, Kiela PR, Frautschy SA, Erickson RP. Lack of efficacy of curcumin on neurodegeneration in the mouse model of Niemann-Pick C1. Pharmacol Biochem Behav 2012;101:125-31. https://doi.org/10.1016/j. pbb.2011.12.009.

[844] Efthymiou AG, Steiner J, Pavan WJ, Wincovitch S, Larson DM, Porter FD, et al. Rescue of an in vitro neuron phenotype identified in Niemann-Pick disease type C1 induced pluripotent stem cell-derived neurons by modulating the WNT pathway and calcium signaling. Stem Cells Transl Med 2015;4:230-8. https://doi. org/10.5966/sctm.2014-0127.

[845] Garcia-Seisdedos D, Babiy B, Lerma M, Casado ME, Martinez-Botas J, Lasuncion MA, et al. Curcumin stimulates exosome/microvesicle release in an in vitro model of intracellular lipid accumulation by increasing ceramide synthesis. Biochim Biophys Acta 2020;1865. https://doi.org/10.1016/j. bbalip.2020.158638.

[846] Smith D, Wallom KL, Williams IM, Jeyakumar M, Platt FM. Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol Dis 2009;36:242-51. https://doi.org/10.1016/j.nbd.2009.07.010.

[847] Hao Y, Pan D, Zhang M, Xu J, Li L, Wei J, et al. The neuroprotective effects of cyclin-dependent kinase-5 inhibition in mice with Niemann-Pick disease type C. J Huazhong Univ Sci Technolog Med Sci 2009;29:324-9. https://doi.org/ 10.1007/s11596-009-0312-0.

[848] Chen FW, Li C, Ioannou YA. Cyclodextrin induces calcium-dependent lysosomal exocytosis. PloS One 2010;5:e15054. https://doi.org/10.1371/journal. pone.0015054.

[849] Cao Q, Zhong XZ, Zou Y, Zhang Z, Toro L, Dong XP. BK Channels alleviate lysosomal storage diseases by providing positive feedback regulation of lysosomal Ca2+ release. Dev Cell 2015;33:427-41. https://doi.org/10.1016/j. devcel.2015.04.010.

[850] Vacca F, Vossio S, Mercier V, Moreau D, Johnson S, Scott CC, et al. Cyclodextrin triggers MCOLN1-dependent endo-lysosome secretion in Niemann-Pick type C cells. J Lipid Res 2019;60:832-43. https://doi.org/10.1194/jlr.M089979.

[851] Feltes M, Gale SE, Moores S, Ory DS, Schaffer JE. Monitoring the itinerary of lysosomal cholesterol in Niemann-Pick Type C1-deficient cells after cyclodextrin treatment. J Lipid Res 2020;61:403-12. https://doi.org/10.1194/jlr. RA119000571.

[852] Arguello G, Balboa E, Tapia PJ, Castro J, Yanez MJ, Mattar P, et al. Genistein activates transcription factor EB and corrects Niemann-Pick C phenotype. Int J Mol Sci 2021;22. https://doi.org/10.3390/ijms22084220.

[853] Kuo SY, Castoreno AB, Aldrich LN, Lassen KG, Goel G, Dančík V, et al. Small-molecule enhancers of autophagy modulate cellular disease phenotypes suggested by human genetics. Proc Natl Acad Sci U S A 2015;112:E4281-7. https://doi.org/ 10.1073/pnas.1512289112.

[854] Fu R, Wassif CA, Yanjanin NM, Watkins-Chow DE, Baxter LL, Incao A, et al. Efficacy of N-acetylcysteine in phenotypic suppression of mouse models of Niemann-Pick disease, type C1. Hum Mol Genet 2013;22:3508-23. https://doi. org/10.1093/hmg/ddt206.

[855] Arguello G, Martinez P, Pena J, Chen O, Platt F, Zanlungo S, et al. Hepatic metabolic response to restricted copper intake in a Niemann-Pick C murine model. Metalomics 2014;6:1527-39. https://doi.org/10.1039/c4mt00056k.

[856] Arguello G, Martinez P, Pena J, Chen O, Platt F, Zanlungo S, et al. Hepatic contribution to cyclodextrin-mediated reversal of cholesterol accumulation in murine NPC1-deficient neurons in vivo. Neurobiol Dis 2021;158:105469. https:// doi.org/10.1016/j.nbd.2021.105469.

[857] Seo Y, Shin Y, Kim HS, Kang I, Hong IS, Choi SW, et al. Donepezil enhances Purkinje cell survival and alleviates motor dysfunction by inhibiting cholesterol synthesis in a murine model of Niemann Pick disease type C. J Neuropathol Exp Neurol 2014;73:234-43. https://doi.org/10.1097/nen.00000000000000045.

[858] Williams IM, Wallom KL, Smith DA, Al Eisa N, Smith C, Platt FM. Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice. Neurobiol Dis 2014;67:9-17. https://doi.org/10.1016/j.nbd.2014.03.001.

[859] Bremova-Ertl T, Claassen J, Foltan T, Gascon-Bayarri J, Gissen P, Hahn A, et al. Efficacy and safety of N-acetyl-l-leucine in Niemann-Pick disease type C. J Neurol 2022;269:1651-62. https://doi.org/10.1007/s00415-021-10717-0.

[860] Cougnoux A, Cluzeau C, Mitra S, Li R, Williams I, Burkert K, et al. Necroptosis in Niemann-Pick disease, type C1: a potential therapeutic target. Cell Death Dis 2016;7:e2147. https://doi.org/10.1038/cddis.2016.16.

[861] Cougnoux A, Clifford S, Salman A, Ng SL, Bertin J, Porter FD. Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin. Mol Genet Metab 2018;125:345-50. https://doi.org/10.1016/j.ymgme.2018.10.009.

[862] Gray J, Fernández-Suárez ME, Falah M, Smith D, Smith C, Kaya E, et al. Heat shock protein amplification improves cerebellar myelination in the Npc1nh mouse model. eBioMedicine 2022;86:104374. https://doi.org/10.1016/j. ebioim.2022.104374.

[863] Mengel E, Patterson MC, Da Riol RM, Del Toro M, Deodato F, Gautschi M, et al. Efficacy and safety of arimogloolim in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment. J Inherit Metab Dis 2021;44:1463-80. https://doi.org/10.1002/ jimd.12428.
[864] Xie C, Gong XM, Luo J, Li BL, Song BL. AAV9-NPC1 significantly ameliorates Purkinje cell death and behavioral abnormalities in mouse NPC disease. J Lipid Res 2017;58:512-8. https://doi.org/10.1194/jlr.M071274.

[865] Chandler RJ, Williams IM, Gibson AL, Davidson CD, Incao AA, Hubbard BT, et al. Systemic AAV9 gene therapy improves the lifespan of mice with Niemann-Pick disease, type C1. Hum Mol Genet 2017;26:52-64. https://doi.org/10.1093/hmg/ddw367.

[866] Hughes MP, Smith DA, Morris L, Fletcher C, Colaco A, Huebecker M, et al. AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease. Hum Mol Genet 2018;27:3079-98. https://doi.org/10.1093/hmg/ddy212.

[867] Markmann S, RJ JC, Rosenberg JB, De BP, Kaminsky SM, Crystal RG, et al. Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AA Vrh.10 vector expressing Npc2. Exp Neurol 2018;306: 22-33. https://doi.org/10.1016/j.expneurol.2018.04.001.

[868] Levy JM, Yeh WH, Pendse N, Davis JR, Hennessey E, Butcher R, et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat Biomed Eng 2020;4:97-110. https://doi.org/10.1038/s41551-019-0501-5.

[869] Davidson CD, Gibson AL, Gu T, Baxter LL, Deverman BE, Beadle K, et al. Improved systemic AAV gene therapy with a neurotrophic capsid in Niemann-Pick disease type C1 mice. Life Sci Allianc 2021;4. https://doi.org/10.26508/lsa.202101040.

[870] Kurokawa Y, Osaka H, Kouga T, Jimbo E, Muramatsu K, Nakamura S, et al. Gene therapy in a mouse model of Niemann-Pick disease type C1. Hum Gene Ther 2021. https://doi.org/10.1089/hum.2020.175.

[871] Ferrante A, Pezzola A, Matteucci A, Di Biase A, Attorri L, Armida M, et al. The adenosine A(2A) receptor agonist T1-11 ameliorates neurovisceral symptoms and extends the lifespan of a mouse model of Niemann-Pick type C disease. Neurobiol Dis 2018;110:1-11. https://doi.org/10.1016/j.nbd.2017.10.013.

[872] Pepponi R, De Simone R, De Nuccio C, Visentin S, Matteucci A, Bernardo A, et al. Repurposing dipyridamole in Niemann Pick type C disease: a proof of concept study. Int J Mol Sci 2022;23. https://doi.org/10.3390/ijms23073456.

[873] Feng X, Bader BM, Yang F, Segura M, Schultz L, Schrooder OHU, et al. Improvement of impaired electrical activity in NPC1 mutant cortical neurons upon DHPG stimulation detected by micro-electrode array. Brain Res 2018;1694: 87-93. https://doi.org/10.1016/j.brainres.2018.05.009.

[874] Kulkarni A, Caporali P, Dolas A, Johny S, Goyal S, Dragotto J, et al. Linear cyclodextrin polymer prodrugs as novel therapeutics for Niemann-Pick type C1 disorder. Sci Rep 2018;8:9547. https://doi.org/10.1038/s41598-018-27926-9.

[875] Houben T, Magro Dos Reis I, Oligschlaeger Y, Steinbusch H, Gijbels MJJ, Hendrikx T, et al. Pneumococcal immunization reduces neurological and hepatic symptoms in a mouse model for Niemann-Pick type C1 disease. Front Immunol 2018;9:3089. https://doi.org/10.3389/fimmu.2018.03089.

[876] Yasmin N, Ishitsuka Y, Fukaura M, Yamada Y, Nakahara S, Ishii A, et al. In vitro and in vivo evaluation of 6-O-α-maltosyl-β-cyclodextrin as a potential therapeutic agent against Niemann-Pick disease type C. Int J Mol Sci 2019;20. https://doi.org/10.3390/ijms20051152.

[877] Park MH, Choi BJ, Jeong MS, Lee JY, Jung IK, Park KH, et al. Characterization of the subventricular-thalamo-cortical circuit in the NP-C mouse brain, and new insights regarding treatment. Mol Ther 2019;27:1507-26. https://doi.org/10.1016/j.ymthe.2019.05.008.

[878] Gascon-Bayarri J, Simon PC, Llop R, Carnaval T, Ledesma MD, Rico I, et al. Efficacy and safety clinical trial with efavirenz in patients diagnosed with adult Niemann-pick type C with cognitive impairment. Medicine 2022;101. https://doi.org/10.1097/md.0000000000031471.

[879] Hung YH, Lotan A, Yeshurun S, Schroeder A, Bush AI. Iron chelation by deferiprone does not rescue the Niemann-Pick Disease Type C1 mouse model. Biometals 2020;33:87-95. https://doi.org/10.1007/s10534-020-00233-5.

[880] Jiang D, Lee H, Pardridge WM. Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes. Sci Rep 2020;10:13334. https://doi.org/10.1038/s41598-020-70290-w.

[881] Han SQ, Zhang HW, Yi MN, Liu XQ, Maegawa GHB, Zou YD, et al. Potential disease-modifying effects of lithium carbonate in Niemann-Pick disease, type C1. Front Pharmacol 2021;12. https://doi.org/10.3389/fphar.2021.667361.

[882] Pipalia NH, Saad SZ, Subramanian K, Cross A, Al-Motawa A, Garg K, et al. HSP90 inhibitors reduce cholesterol storage in Niemann-Pick type C1 mutant fibroblasts. J Lipid Res 2021;62. https://doi.org/10.1016/j.jlr.2021.100114.

[883] Van Hoecke L, Van Cauwenberghe C, Boerger V, Bruggeman A, Castelein J, Van Imschoot G, et al. Anti-inflammatory mesenchymal stromal cell-derived extracellular vesicles improve pathology in Niemann-Pick type C disease. Biomedicines 2021;9. https://doi.org/10.3390/biomedicines9121864.

[884] Kang I, Yoo JM, Kim D, Kim J, Cho MK, Lee SE, et al. Graphene quantum dots alleviate impaired functions in Niemann-Pick disease type C in vivo. Nano Lett 2021;21:2339-46. https://doi.org/10.1021/acs.nanolett.0c03741.

[885] Scotto Rosato A, Krogsaeter EK, Jašlan D, Abrahamian C, Montefusco S, Soldati C, et al. TPC2 rescues lysosomal storage in mucolipidosis type IV, Niemann-Pick type C1, and Batten disease. EMBO Mol Med 2022;14:e15377. https://doi.org/10.15252/emmm.202115377.

[886] Furtado D, Cortez-Jugo C, Hung YH, Bush AI, Caruso F. mRNA treatment rescues Niemann-Pick disease type C1 in patient fibroblasts. Mol Pharm 2022;19: 3987-99. https://doi.org/10.1021/acs.molpharmaceut.2c00463.

[887] Diaz GA, Jones SA, Scarpa M, Mengel KE, Giugliani R, Guffon N, et al. One-year results of a clinical trial of olipudase alfa enzyme replacement therapy in pediatric patients with acid sphingomyelinase deficiency. Genet Med 2021;23:1543-50. https://doi.org/10.1038/s41436-021-01156-3.

[888] Yanez MJ, Marin T, Balboa E, Klein AD, Alvarez AR, Zanlungo S. Finding pathogenic commonalities between Niemann-Pick type C and other lysosomal storage disorders: Opportunities for shared therapeutic interventions. BBA-Mol Basis Dis 2020;1866. https://doi.org/10.1016/j.bbadis.2020.165875.

[889] Pfrieger FW. TeamTree analysis: A new approach to evaluate scientific production. PloS One 2021;16:e0253847. https://doi.org/10.1371/journal.pone.0253847.

[890] Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2021.